[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fmo6CCINHNV3-flrfaNCBB8nrs3h0are_pC4BPUNPbWc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":86,"rows":93},"ModernaTX, Inc.",[4],111,false,30,23,66623630,35,13,[14,17,19,22,25,28,31,34],{"name":15,"count":16},"SARS-CoV-2",31,{"name":18,"count":12},"Influenza",{"name":20,"count":21},"Respiratory Syncytial Virus",11,{"name":23,"count":24},"Seasonal Influenza",8,{"name":26,"count":27},"Cytomegalovirus Infection",7,{"name":29,"count":30},"COVID-19",5,{"name":32,"count":33},"Propionic Acidemia",4,{"name":35,"count":36},"Zika Virus",3,[38,43,48,53,58,62,67,71,76,81],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT06143046","A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers","2026-05-27","mRNA-1345",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT07089706","A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations","2026-06-19","mRNA-1283.251 Variant-containing Formulation",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT06655870","A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants","2026-06-23","mRNA-0184",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT05701800","A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age","2026-06-30","mRNA-1468",{"nctId":59,"briefTitle":60,"date":61,"intervention":42},"NCT06067230","A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults","2026-07-30",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05683457","A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.","2026-08-01","mRNA-1647",{"nctId":68,"briefTitle":69,"date":70,"intervention":42},"NCT05743881","A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to \u003C24 Months","2026-08-31",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT05992935","Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age","2026-09-22","mRNA-1403",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT05164094","A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults","2026-10-05","mRNA-1189",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT05831111","A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants","2026-10-07","mRNA-1195.1",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,143,164,188,309,438,471,495,556,596,685,707,741,769,804,838,864,886,904,922,947,965,983,1001,1041,1059,1077,1095,1113,1131,1149,1167,1194,1212,1230,1248,1273,1391,1443,1509,1542,1568,1606,1628,1650,1675,1693,1711,1729,1747,1765,1783,1801,1819,1837,1855,1873,1891,1909,1927,1945,1963,2002,2034,2056,2078,2096,2114,2132,2150,2168,2186,2204,2222,2240,2258,2276,2294,2312,2330,2348,2366,2384,2402,2428,2446,2464,2482,2500,2525,2543,2561,2579,2597,2615,2633,2658,2683,2701,2719,2737,2755,2773,2791,2809,2827,2845,2863,2881,2899,2927,2945,2963,2981,2999,3025,3043,3077,3101,3126,3149,3167,3191,3209,3233,3257,3275,3296,3314,3346,3374,3392,3410,3428,3446],{"intervention":95,"totalTrials":36,"cells":96},"mRNA-1283",{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":113,"PHASE3":126,"PHASE4":128,"NA":141},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[102],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":111},"NCT04813796","A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19","COMPLETED",[88],"2023-07-25","2021-03-11",104,[15],[95,112],"mRNA-1273",{"trials":114,"activeCount":99},[115],{"nctId":116,"briefTitle":117,"status":105,"phases":118,"primaryCompletion":119,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":123},"NCT05137236","A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters",[89],"2023-03-23","2021-12-06",540,[15],[95,124,112,125],"mRNA-1283.211","mRNA-1283.529",{"trials":127,"activeCount":99},[],{"trials":129,"activeCount":140,"soonestReadout":135},[130],{"nctId":131,"briefTitle":132,"status":133,"phases":134,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":139},"NCT07266558","A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)","ACTIVE_NOT_RECRUITING",[91],"2027-06-16","2025-11-26",30000,[15],[112,95],1,{"trials":142,"activeCount":99},[],{"intervention":47,"totalTrials":140,"cells":144},{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":149,"PHASE3":151,"PHASE4":153,"NA":162},{"trials":146,"activeCount":99},[],{"trials":148,"activeCount":99},[],{"trials":150,"activeCount":99},[],{"trials":152,"activeCount":99},[],{"trials":154,"activeCount":140,"soonestReadout":46},[155],{"nctId":44,"briefTitle":45,"status":156,"phases":157,"primaryCompletion":46,"completion":46,"start":158,"enrollment":159,"conditions":160,"interventions":161},"RECRUITING",[91],"2025-07-21",832,[29],[47],{"trials":163,"activeCount":99},[],{"intervention":165,"totalTrials":140,"cells":166},"mRNA-1273 Variant-containing Formulation",{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":171,"PHASE3":173,"PHASE4":175,"NA":186},{"trials":168,"activeCount":99},[],{"trials":170,"activeCount":99},[],{"trials":172,"activeCount":99},[],{"trials":174,"activeCount":99},[],{"trials":176,"activeCount":140,"soonestReadout":181},[177],{"nctId":178,"briefTitle":179,"status":156,"phases":180,"primaryCompletion":181,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":185},"NCT06585241","A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations",[91],"2026-12-31","2024-09-09",1144,[15],[165],{"trials":187,"activeCount":99},[],{"intervention":112,"totalTrials":189,"cells":190},12,{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":211,"PHASE3":227,"PHASE4":290,"NA":296},{"trials":192,"activeCount":99},[],{"trials":194,"activeCount":99},[195,199],{"nctId":103,"briefTitle":104,"status":105,"phases":196,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":197,"interventions":198},[88],[15],[95,112],{"nctId":200,"briefTitle":201,"status":105,"phases":202,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":208},"NCT05397223","A Study of Modified mRNA Vaccines in Healthy Adults",[88],"2026-02-27","2022-05-24",308,[15,23,20,207],"Cytomegalovirus",[112,209,42,210,66],"mRNA-1010","FLUAD®",{"trials":212,"activeCount":99},[213,217],{"nctId":116,"briefTitle":117,"status":105,"phases":214,"primaryCompletion":119,"completion":119,"start":120,"enrollment":121,"conditions":215,"interventions":216},[89],[15],[95,124,112,125],{"nctId":218,"briefTitle":219,"status":105,"phases":220,"primaryCompletion":221,"completion":221,"start":222,"enrollment":223,"conditions":224,"interventions":225},"NCT05375838","A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19\u002FInfluenza) Vaccine in Adults 18 to 75 Years Old",[88,89],"2022-12-29","2022-05-13",550,[15,18],[226,209,112],"mRNA-1073",{"trials":228,"activeCount":99},[229,239,247,263,272,281],{"nctId":230,"briefTitle":231,"status":105,"phases":232,"primaryCompletion":233,"completion":233,"start":234,"enrollment":235,"conditions":236,"interventions":237},"NCT04796896","A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age",[89,90],"2024-03-15","2021-03-15",11942,[15],[112,238],"mRNA-1273.214",{"nctId":240,"briefTitle":241,"status":105,"phases":242,"primaryCompletion":221,"completion":221,"start":243,"enrollment":244,"conditions":245,"interventions":246},"NCT04470427","A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19",[90],"2020-07-27",30415,[15],[112],{"nctId":248,"briefTitle":249,"status":105,"phases":250,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":255},"NCT04927065","A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants",[89,90],"2023-11-17","2021-05-28",5161,[15],[256,112,257,258,259,238,260,261,262],"mRNA-1273.211","mRNA-1273.617.2","mRNA-1273.213","mRNA-1273.529","mRNA-1273.222","mRNA-1273.815","mRNA-1273.231",{"nctId":264,"briefTitle":265,"status":105,"phases":266,"primaryCompletion":267,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":271},"NCT04649151","A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to \u003C18 Years Old to Prevent COVID-19",[89,90],"2024-06-14","2020-12-09",4328,[15],[112,260],{"nctId":273,"briefTitle":274,"status":105,"phases":275,"primaryCompletion":276,"completion":276,"start":277,"enrollment":278,"conditions":279,"interventions":280},"NCT04860297","A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants",[90],"2023-05-22","2021-04-16",234,[15],[112],{"nctId":282,"briefTitle":283,"status":105,"phases":284,"primaryCompletion":285,"completion":285,"start":286,"enrollment":287,"conditions":288,"interventions":289},"NCT05249829","A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19",[89,90],"2023-06-23","2022-02-16",3548,[15],[259,112,238],{"trials":291,"activeCount":140,"soonestReadout":135},[292],{"nctId":131,"briefTitle":132,"status":133,"phases":293,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":294,"interventions":295},[91],[15],[112,95],{"trials":297,"activeCount":99},[298],{"nctId":299,"briefTitle":300,"status":105,"phases":301,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":308},"NCT06113692","A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine",[],"2024-08-31","2025-06-30","2023-03-31",1169,[307],"Myocarditis, Pericarditis",[112],{"intervention":42,"totalTrials":12,"cells":310},{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":350,"PHASE3":379,"PHASE4":425,"NA":427},{"trials":312,"activeCount":99},[],{"trials":314,"activeCount":140,"soonestReadout":70},[315,319,328,340],{"nctId":200,"briefTitle":201,"status":105,"phases":316,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":317,"interventions":318},[88],[15,23,20,207],[112,209,42,210,66],{"nctId":320,"briefTitle":321,"status":105,"phases":322,"primaryCompletion":323,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":327},"NCT04528719","A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive",[88],"2024-07-18","2020-09-30",651,[20],[42],{"nctId":329,"briefTitle":330,"status":105,"phases":331,"primaryCompletion":332,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":337},"NCT05585632","A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old",[88],"2024-02-28","2022-10-14",392,[15,18,336],"RSV",[209,42,238,338,339],"mRNA-1045","mRNA-1230",{"nctId":68,"briefTitle":69,"status":133,"phases":341,"primaryCompletion":70,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":347},[88],"2026-09-30","2023-02-15",186,[20,346],"Human Metapneumovirus",[42,348,349],"mRNA-1365","Nimenrix",{"trials":351,"activeCount":140,"soonestReadout":41},[352,358,370],{"nctId":39,"briefTitle":40,"status":133,"phases":353,"primaryCompletion":41,"completion":41,"start":354,"enrollment":355,"conditions":356,"interventions":357},[89],"2023-11-15",360,[20],[42],{"nctId":359,"briefTitle":360,"status":105,"phases":361,"primaryCompletion":362,"completion":362,"start":363,"enrollment":364,"conditions":365,"interventions":366},"NCT05606965","A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults",[89],"2025-11-13","2022-11-02",172,[18],[209,367,368,369,42,338],"Egg-based Quadrivalent Influenza Vaccine","Adjuvanted Quadrivalent Influenza Vaccine","Inactivated Influenza Vaccine",{"nctId":371,"briefTitle":372,"status":105,"phases":373,"primaryCompletion":374,"completion":374,"start":375,"enrollment":376,"conditions":377,"interventions":378},"NCT06097299","A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to \u003C18 Years of Age at High Risk of Respiratory Syncytial Virus",[89],"2025-06-27","2023-10-24",346,[20],[42],{"trials":380,"activeCount":140,"soonestReadout":61},[381,390,399,409,415],{"nctId":382,"briefTitle":383,"status":105,"phases":384,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":388,"interventions":389},"NCT07117487","A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age",[90],"2026-03-27","2025-08-05",507,[20],[42],{"nctId":391,"briefTitle":392,"status":105,"phases":393,"primaryCompletion":394,"completion":394,"start":395,"enrollment":396,"conditions":397,"interventions":398},"NCT05127434","A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age",[89,90],"2025-07-28","2021-11-17",36814,[20],[42],{"nctId":400,"briefTitle":401,"status":105,"phases":402,"primaryCompletion":403,"completion":403,"start":404,"enrollment":405,"conditions":406,"interventions":407},"NCT05330975","A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age",[90],"2024-11-08","2022-04-01",3317,[20],[42,408,238],"Afluria® Quadrivalent",{"nctId":59,"briefTitle":60,"status":133,"phases":410,"primaryCompletion":61,"completion":61,"start":411,"enrollment":412,"conditions":413,"interventions":414},[90],"2023-10-06",1153,[20],[42],{"nctId":416,"briefTitle":417,"status":105,"phases":418,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":423},"NCT06060457","A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age",[90],"2024-06-07","2023-09-25",1900,[20],[42,424],"Fluzone HD",{"trials":426,"activeCount":99},[],{"trials":428,"activeCount":99},[429],{"nctId":430,"briefTitle":431,"status":105,"phases":432,"primaryCompletion":433,"completion":433,"start":434,"enrollment":435,"conditions":436,"interventions":437},"NCT05572658","Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study",[],"2023-09-30","2022-09-15",10994,[20],[42],{"intervention":75,"totalTrials":439,"cells":440},2,{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":455,"PHASE4":467,"NA":469},{"trials":442,"activeCount":99},[],{"trials":444,"activeCount":99},[],{"trials":446,"activeCount":140,"soonestReadout":74},[447],{"nctId":72,"briefTitle":73,"status":133,"phases":448,"primaryCompletion":74,"completion":74,"start":449,"enrollment":450,"conditions":451,"interventions":453},[88,89],"2023-08-25",1407,[452],"Norovirus Acute Gastroenteritis",[75,454],"mRNA-1405",{"trials":456,"activeCount":140,"soonestReadout":461},[457],{"nctId":458,"briefTitle":459,"status":133,"phases":460,"primaryCompletion":461,"completion":461,"start":462,"enrollment":463,"conditions":464,"interventions":466},"NCT06592794","A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis",[90],"2027-02-15","2024-09-24",37864,[465,452],"Acute Gastroenteritis",[75],{"trials":468,"activeCount":99},[],{"trials":470,"activeCount":99},[],{"intervention":472,"totalTrials":140,"cells":473},"mRNA-1018-H5",{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":480,"PHASE4":491,"NA":493},{"trials":475,"activeCount":99},[],{"trials":477,"activeCount":99},[],{"trials":479,"activeCount":99},[],{"trials":481,"activeCount":140,"soonestReadout":486},[482],{"nctId":483,"briefTitle":484,"status":156,"phases":485,"primaryCompletion":486,"completion":486,"start":487,"enrollment":488,"conditions":489,"interventions":490},"NCT07496450","A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults",[90],"2027-01-28","2026-03-23",4000,[18],[472],{"trials":492,"activeCount":99},[],{"trials":494,"activeCount":99},[],{"intervention":496,"totalTrials":33,"cells":497},"Pembrolizumab",{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":526,"PHASE3":550,"PHASE4":552,"NA":554},{"trials":499,"activeCount":99},[],{"trials":501,"activeCount":439,"soonestReadout":518},[502,514],{"nctId":503,"briefTitle":504,"status":133,"phases":505,"primaryCompletion":506,"completion":506,"start":507,"enrollment":508,"conditions":509,"interventions":511},"NCT03313778","Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors",[88],"2027-11-21","2017-08-14",161,[510],"Solid Tumors",[512,496,513],"mRNA-4157","SoC Treatment",{"nctId":515,"briefTitle":516,"status":133,"phases":517,"primaryCompletion":518,"completion":518,"start":519,"enrollment":520,"conditions":521,"interventions":523},"NCT06880549","A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors",[88],"2027-08-03","2025-03-25",42,[522],"Advanced Solid Tumors",[524,496,525],"mRNA-4106","mRNA-4200",{"trials":527,"activeCount":439,"soonestReadout":542},[528,538],{"nctId":529,"briefTitle":530,"status":133,"phases":531,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":535,"interventions":537},"NCT03897881","An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)",[89],"2032-11-30","2019-07-18",267,[536],"Melanoma",[512,496],{"nctId":539,"briefTitle":540,"status":156,"phases":541,"primaryCompletion":542,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":546},"NCT05533697","Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors",[88,89],"2032-02-18","2022-09-01",361,[522],[547,496,548,549],"mRNA-4359","Ipilimumab","Nivolumab",{"trials":551,"activeCount":99},[],{"trials":553,"activeCount":99},[],{"trials":555,"activeCount":99},[],{"intervention":80,"totalTrials":36,"cells":557},{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":581,"PHASE3":590,"PHASE4":592,"NA":594},{"trials":559,"activeCount":99},[],{"trials":561,"activeCount":439,"soonestReadout":84},[562,572],{"nctId":563,"briefTitle":564,"status":156,"phases":565,"primaryCompletion":566,"completion":566,"start":567,"enrollment":568,"conditions":569,"interventions":571},"NCT07478952","A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age",[88],"2027-05-15","2026-03-17",120,[570],"Epstein-Barr Virus",[80],{"nctId":82,"briefTitle":83,"status":133,"phases":573,"primaryCompletion":84,"completion":84,"start":574,"enrollment":575,"conditions":576,"interventions":578},[88],"2023-04-05",482,[577],"Epstein-Barr Virus Infection",[85,579,80,580],"mRNA-1195.2","mRNA-1195",{"trials":582,"activeCount":140,"soonestReadout":79},[583],{"nctId":77,"briefTitle":78,"status":133,"phases":584,"primaryCompletion":79,"completion":585,"start":586,"enrollment":587,"conditions":588,"interventions":589},[88,89],"2027-08-18","2021-12-28",867,[577],[80],{"trials":591,"activeCount":99},[],{"trials":593,"activeCount":99},[],{"trials":595,"activeCount":99},[],{"intervention":66,"totalTrials":597,"cells":598},9,{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":625,"PHASE3":669,"PHASE4":681,"NA":683},{"trials":600,"activeCount":99},[],{"trials":602,"activeCount":99},[603,607,615],{"nctId":200,"briefTitle":201,"status":105,"phases":604,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":605,"interventions":606},[88],[15,23,20,207],[112,209,42,210,66],{"nctId":608,"briefTitle":609,"status":105,"phases":610,"primaryCompletion":611,"completion":611,"start":612,"enrollment":597,"conditions":613,"interventions":614},"NCT05105048","A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647",[88],"2023-08-10","2021-11-08",[26],[66],{"nctId":616,"briefTitle":617,"status":105,"phases":618,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":622,"interventions":623},"NCT03382405","Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults",[88],"2020-10-28","2017-11-13",181,[26],[66,624],"mRNA-1443",{"trials":626,"activeCount":439,"soonestReadout":65},[627,636,646,651,660],{"nctId":628,"briefTitle":629,"status":133,"phases":630,"primaryCompletion":631,"completion":631,"start":632,"enrollment":633,"conditions":634,"interventions":635},"NCT05575492","A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age",[88,89],"2027-01-15","2022-11-07",873,[207],[66],{"nctId":637,"briefTitle":638,"status":639,"phases":640,"primaryCompletion":641,"completion":642,"start":643,"enrollment":99,"conditions":644,"interventions":645},"NCT06133010","A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients","WITHDRAWN",[89],"2027-02-14","2027-12-14","2024-02-08",[26],[66],{"nctId":63,"briefTitle":64,"status":133,"phases":647,"primaryCompletion":65,"completion":65,"start":574,"enrollment":648,"conditions":649,"interventions":650},[89],84,[26],[66],{"nctId":652,"briefTitle":653,"status":105,"phases":654,"primaryCompletion":655,"completion":655,"start":656,"enrollment":657,"conditions":658,"interventions":659},"NCT04232280","Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults",[89],"2023-01-04","2020-01-09",315,[26],[66],{"nctId":661,"briefTitle":662,"status":105,"phases":663,"primaryCompletion":664,"completion":664,"start":665,"enrollment":666,"conditions":667,"interventions":668},"NCT04975893","A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine",[89],"2026-01-19","2021-06-18",135,[26],[66],{"trials":670,"activeCount":99},[671],{"nctId":672,"briefTitle":673,"status":674,"phases":675,"primaryCompletion":676,"completion":676,"start":677,"enrollment":678,"conditions":679,"interventions":680},"NCT05085366","A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age","TERMINATED",[90],"2025-11-04","2021-10-26",7454,[26],[66],{"trials":682,"activeCount":99},[],{"trials":684,"activeCount":99},[],{"intervention":512,"totalTrials":439,"cells":686},{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":695,"PHASE3":701,"PHASE4":703,"NA":705},{"trials":688,"activeCount":99},[],{"trials":690,"activeCount":140,"soonestReadout":506},[691],{"nctId":503,"briefTitle":504,"status":133,"phases":692,"primaryCompletion":506,"completion":506,"start":507,"enrollment":508,"conditions":693,"interventions":694},[88],[510],[512,496,513],{"trials":696,"activeCount":140,"soonestReadout":532},[697],{"nctId":529,"briefTitle":530,"status":133,"phases":698,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":699,"interventions":700},[89],[536],[512,496],{"trials":702,"activeCount":99},[],{"trials":704,"activeCount":99},[],{"trials":706,"activeCount":99},[],{"intervention":708,"totalTrials":439,"cells":709},"mRNA-3927",{"EARLY_PHASE1":710,"PHASE1":712,"PHASE2":714,"PHASE3":735,"PHASE4":737,"NA":739},{"trials":711,"activeCount":99},[],{"trials":713,"activeCount":99},[],{"trials":715,"activeCount":439,"soonestReadout":730},[716,726],{"nctId":717,"briefTitle":718,"status":156,"phases":719,"primaryCompletion":720,"completion":721,"start":722,"enrollment":723,"conditions":724,"interventions":725},"NCT05130437","A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study",[88,89],"2029-12-04","2031-12-04","2021-11-09",50,[32],[708],{"nctId":727,"briefTitle":728,"status":156,"phases":729,"primaryCompletion":730,"completion":730,"start":731,"enrollment":732,"conditions":733,"interventions":734},"NCT04159103","Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia",[88,89],"2027-08-31","2021-04-15",77,[32],[708],{"trials":736,"activeCount":99},[],{"trials":738,"activeCount":99},[],{"trials":740,"activeCount":99},[],{"intervention":580,"totalTrials":439,"cells":742},{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":751,"PHASE3":763,"PHASE4":765,"NA":767},{"trials":744,"activeCount":99},[],{"trials":746,"activeCount":140,"soonestReadout":84},[747],{"nctId":82,"briefTitle":83,"status":133,"phases":748,"primaryCompletion":84,"completion":84,"start":574,"enrollment":575,"conditions":749,"interventions":750},[88],[577],[85,579,80,580],{"trials":752,"activeCount":140,"soonestReadout":757},[753],{"nctId":754,"briefTitle":755,"status":156,"phases":756,"primaryCompletion":757,"completion":757,"start":758,"enrollment":759,"conditions":760,"interventions":762},"NCT06735248","A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years",[89],"2029-01-08","2025-04-16",180,[761],"Multiple Sclerosis",[580],{"trials":764,"activeCount":99},[],{"trials":766,"activeCount":99},[],{"trials":768,"activeCount":99},[],{"intervention":770,"totalTrials":439,"cells":771},"mRNA-1982",{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":798,"PHASE4":800,"NA":802},{"trials":773,"activeCount":99},[],{"trials":775,"activeCount":99},[],{"trials":777,"activeCount":140,"soonestReadout":793},[778,789],{"nctId":779,"briefTitle":780,"status":105,"phases":781,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":785,"interventions":787},"NCT05975099","A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age",[88,89],"2025-05-30","2023-07-26",807,[786],"Lyme Disease",[788,770],"mRNA-1975",{"nctId":790,"briefTitle":791,"status":156,"phases":792,"primaryCompletion":793,"completion":793,"start":794,"enrollment":795,"conditions":796,"interventions":797},"NCT07561294","A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)",[89],"2028-11-09","2026-04-29",350,[786],[770],{"trials":799,"activeCount":99},[],{"trials":801,"activeCount":99},[],{"trials":803,"activeCount":99},[],{"intervention":805,"totalTrials":439,"cells":806},"mRNA-3705",{"EARLY_PHASE1":807,"PHASE1":809,"PHASE2":811,"PHASE3":832,"PHASE4":834,"NA":836},{"trials":808,"activeCount":99},[],{"trials":810,"activeCount":99},[],{"trials":812,"activeCount":140,"soonestReadout":827},[813,823],{"nctId":814,"briefTitle":815,"status":674,"phases":816,"primaryCompletion":817,"completion":817,"start":818,"enrollment":819,"conditions":820,"interventions":822},"NCT04899310","A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia",[88,89],"2026-04-01","2021-08-06",18,[821],"Methylmalonic Acidemia",[805],{"nctId":824,"briefTitle":825,"status":156,"phases":826,"primaryCompletion":827,"completion":827,"start":828,"enrollment":829,"conditions":830,"interventions":831},"NCT05295433","An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705",[88,89],"2034-04-02","2022-03-08",56,[821],[805],{"trials":833,"activeCount":99},[],{"trials":835,"activeCount":99},[],{"trials":837,"activeCount":99},[],{"intervention":839,"totalTrials":140,"cells":840},"mRNA-2808",{"EARLY_PHASE1":841,"PHASE1":843,"PHASE2":845,"PHASE3":858,"PHASE4":860,"NA":862},{"trials":842,"activeCount":99},[],{"trials":844,"activeCount":99},[],{"trials":846,"activeCount":140,"soonestReadout":851},[847],{"nctId":848,"briefTitle":849,"status":156,"phases":850,"primaryCompletion":851,"completion":852,"start":853,"enrollment":854,"conditions":855,"interventions":857},"NCT07116616","A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma",[88,89],"2030-06-17","2032-06-17","2025-09-30",166,[856],"Relapsed or Refractory Multiple Myeloma",[839],{"trials":859,"activeCount":99},[],{"trials":861,"activeCount":99},[],{"trials":863,"activeCount":99},[],{"intervention":57,"totalTrials":140,"cells":865},{"EARLY_PHASE1":866,"PHASE1":868,"PHASE2":870,"PHASE3":880,"PHASE4":882,"NA":884},{"trials":867,"activeCount":99},[],{"trials":869,"activeCount":99},[],{"trials":871,"activeCount":140,"soonestReadout":56},[872],{"nctId":54,"briefTitle":55,"status":133,"phases":873,"primaryCompletion":56,"completion":56,"start":874,"enrollment":875,"conditions":876,"interventions":878},[88,89],"2023-01-23",659,[877],"Herpes Zoster",[57,879],"Shingrix",{"trials":881,"activeCount":99},[],{"trials":883,"activeCount":99},[],{"trials":885,"activeCount":99},[],{"intervention":879,"totalTrials":140,"cells":887},{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":892,"PHASE3":898,"PHASE4":900,"NA":902},{"trials":889,"activeCount":99},[],{"trials":891,"activeCount":99},[],{"trials":893,"activeCount":140,"soonestReadout":56},[894],{"nctId":54,"briefTitle":55,"status":133,"phases":895,"primaryCompletion":56,"completion":56,"start":874,"enrollment":875,"conditions":896,"interventions":897},[88,89],[877],[57,879],{"trials":899,"activeCount":99},[],{"trials":901,"activeCount":99},[],{"trials":903,"activeCount":99},[],{"intervention":454,"totalTrials":140,"cells":905},{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":916,"PHASE4":918,"NA":920},{"trials":907,"activeCount":99},[],{"trials":909,"activeCount":99},[],{"trials":911,"activeCount":140,"soonestReadout":74},[912],{"nctId":72,"briefTitle":73,"status":133,"phases":913,"primaryCompletion":74,"completion":74,"start":449,"enrollment":450,"conditions":914,"interventions":915},[88,89],[452],[75,454],{"trials":917,"activeCount":99},[],{"trials":919,"activeCount":99},[],{"trials":921,"activeCount":99},[],{"intervention":923,"totalTrials":140,"cells":924},"mRNA-3745",{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":941,"PHASE4":943,"NA":945},{"trials":926,"activeCount":99},[],{"trials":928,"activeCount":99},[],{"trials":930,"activeCount":140,"soonestReadout":935},[931],{"nctId":932,"briefTitle":933,"status":133,"phases":934,"primaryCompletion":935,"completion":935,"start":936,"enrollment":937,"conditions":938,"interventions":940},"NCT05095727","A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)",[88,89],"2026-11-30","2022-06-01",15,[939],"Glycogen Storage Disease",[923],{"trials":942,"activeCount":99},[],{"trials":944,"activeCount":99},[],{"trials":946,"activeCount":99},[],{"intervention":547,"totalTrials":140,"cells":948},{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":959,"PHASE4":961,"NA":963},{"trials":950,"activeCount":99},[],{"trials":952,"activeCount":99},[],{"trials":954,"activeCount":140,"soonestReadout":542},[955],{"nctId":539,"briefTitle":540,"status":156,"phases":956,"primaryCompletion":542,"completion":542,"start":543,"enrollment":544,"conditions":957,"interventions":958},[88,89],[522],[547,496,548,549],{"trials":960,"activeCount":99},[],{"trials":962,"activeCount":99},[],{"trials":964,"activeCount":99},[],{"intervention":548,"totalTrials":140,"cells":966},{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":977,"PHASE4":979,"NA":981},{"trials":968,"activeCount":99},[],{"trials":970,"activeCount":99},[],{"trials":972,"activeCount":140,"soonestReadout":542},[973],{"nctId":539,"briefTitle":540,"status":156,"phases":974,"primaryCompletion":542,"completion":542,"start":543,"enrollment":544,"conditions":975,"interventions":976},[88,89],[522],[547,496,548,549],{"trials":978,"activeCount":99},[],{"trials":980,"activeCount":99},[],{"trials":982,"activeCount":99},[],{"intervention":549,"totalTrials":140,"cells":984},{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":995,"PHASE4":997,"NA":999},{"trials":986,"activeCount":99},[],{"trials":988,"activeCount":99},[],{"trials":990,"activeCount":140,"soonestReadout":542},[991],{"nctId":539,"briefTitle":540,"status":156,"phases":992,"primaryCompletion":542,"completion":542,"start":543,"enrollment":544,"conditions":993,"interventions":994},[88,89],[522],[547,496,548,549],{"trials":996,"activeCount":99},[],{"trials":998,"activeCount":99},[],{"trials":1000,"activeCount":99},[],{"intervention":52,"totalTrials":36,"cells":1002},{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1033,"PHASE3":1035,"PHASE4":1037,"NA":1039},{"trials":1004,"activeCount":99},[],{"trials":1006,"activeCount":140,"soonestReadout":51},[1007,1014,1023],{"nctId":49,"briefTitle":50,"status":133,"phases":1008,"primaryCompletion":51,"completion":51,"start":1009,"enrollment":1010,"conditions":1011,"interventions":1013},[88],"2024-10-31",52,[1012],"Healthy Participants",[52],{"nctId":1015,"briefTitle":1016,"status":105,"phases":1017,"primaryCompletion":1018,"completion":1018,"start":1019,"enrollment":1020,"conditions":1021,"interventions":1022},"NCT06243770","Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy Participants",[88],"2025-06-12","2024-02-16",44,[1012],[52],{"nctId":1024,"briefTitle":1025,"status":105,"phases":1026,"primaryCompletion":1027,"completion":1027,"start":1028,"enrollment":1029,"conditions":1030,"interventions":1032},"NCT05659264","A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure",[88],"2024-12-17","2022-12-05",48,[1031],"Chronic Heart Failure",[52],{"trials":1034,"activeCount":99},[],{"trials":1036,"activeCount":99},[],{"trials":1038,"activeCount":99},[],{"trials":1040,"activeCount":99},[],{"intervention":513,"totalTrials":140,"cells":1042},{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1051,"PHASE3":1053,"PHASE4":1055,"NA":1057},{"trials":1044,"activeCount":99},[],{"trials":1046,"activeCount":140,"soonestReadout":506},[1047],{"nctId":503,"briefTitle":504,"status":133,"phases":1048,"primaryCompletion":506,"completion":506,"start":507,"enrollment":508,"conditions":1049,"interventions":1050},[88],[510],[512,496,513],{"trials":1052,"activeCount":99},[],{"trials":1054,"activeCount":99},[],{"trials":1056,"activeCount":99},[],{"trials":1058,"activeCount":99},[],{"intervention":85,"totalTrials":140,"cells":1060},{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1069,"PHASE3":1071,"PHASE4":1073,"NA":1075},{"trials":1062,"activeCount":99},[],{"trials":1064,"activeCount":140,"soonestReadout":84},[1065],{"nctId":82,"briefTitle":83,"status":133,"phases":1066,"primaryCompletion":84,"completion":84,"start":574,"enrollment":575,"conditions":1067,"interventions":1068},[88],[577],[85,579,80,580],{"trials":1070,"activeCount":99},[],{"trials":1072,"activeCount":99},[],{"trials":1074,"activeCount":99},[],{"trials":1076,"activeCount":99},[],{"intervention":579,"totalTrials":140,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1087,"PHASE3":1089,"PHASE4":1091,"NA":1093},{"trials":1080,"activeCount":99},[],{"trials":1082,"activeCount":140,"soonestReadout":84},[1083],{"nctId":82,"briefTitle":83,"status":133,"phases":1084,"primaryCompletion":84,"completion":84,"start":574,"enrollment":575,"conditions":1085,"interventions":1086},[88],[577],[85,579,80,580],{"trials":1088,"activeCount":99},[],{"trials":1090,"activeCount":99},[],{"trials":1092,"activeCount":99},[],{"trials":1094,"activeCount":99},[],{"intervention":524,"totalTrials":140,"cells":1096},{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1105,"PHASE3":1107,"PHASE4":1109,"NA":1111},{"trials":1098,"activeCount":99},[],{"trials":1100,"activeCount":140,"soonestReadout":518},[1101],{"nctId":515,"briefTitle":516,"status":133,"phases":1102,"primaryCompletion":518,"completion":518,"start":519,"enrollment":520,"conditions":1103,"interventions":1104},[88],[522],[524,496,525],{"trials":1106,"activeCount":99},[],{"trials":1108,"activeCount":99},[],{"trials":1110,"activeCount":99},[],{"trials":1112,"activeCount":99},[],{"intervention":525,"totalTrials":140,"cells":1114},{"EARLY_PHASE1":1115,"PHASE1":1117,"PHASE2":1123,"PHASE3":1125,"PHASE4":1127,"NA":1129},{"trials":1116,"activeCount":99},[],{"trials":1118,"activeCount":140,"soonestReadout":518},[1119],{"nctId":515,"briefTitle":516,"status":133,"phases":1120,"primaryCompletion":518,"completion":518,"start":519,"enrollment":520,"conditions":1121,"interventions":1122},[88],[522],[524,496,525],{"trials":1124,"activeCount":99},[],{"trials":1126,"activeCount":99},[],{"trials":1128,"activeCount":99},[],{"trials":1130,"activeCount":99},[],{"intervention":348,"totalTrials":140,"cells":1132},{"EARLY_PHASE1":1133,"PHASE1":1135,"PHASE2":1141,"PHASE3":1143,"PHASE4":1145,"NA":1147},{"trials":1134,"activeCount":99},[],{"trials":1136,"activeCount":140,"soonestReadout":70},[1137],{"nctId":68,"briefTitle":69,"status":133,"phases":1138,"primaryCompletion":70,"completion":342,"start":343,"enrollment":344,"conditions":1139,"interventions":1140},[88],[20,346],[42,348,349],{"trials":1142,"activeCount":99},[],{"trials":1144,"activeCount":99},[],{"trials":1146,"activeCount":99},[],{"trials":1148,"activeCount":99},[],{"intervention":349,"totalTrials":140,"cells":1150},{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1159,"PHASE3":1161,"PHASE4":1163,"NA":1165},{"trials":1152,"activeCount":99},[],{"trials":1154,"activeCount":140,"soonestReadout":70},[1155],{"nctId":68,"briefTitle":69,"status":133,"phases":1156,"primaryCompletion":70,"completion":342,"start":343,"enrollment":344,"conditions":1157,"interventions":1158},[88],[20,346],[42,348,349],{"trials":1160,"activeCount":99},[],{"trials":1162,"activeCount":99},[],{"trials":1164,"activeCount":99},[],{"trials":1166,"activeCount":99},[],{"intervention":1168,"totalTrials":140,"cells":1169},"SPIKEVAX Bivalent BA.1",{"EARLY_PHASE1":1170,"PHASE1":1172,"PHASE2":1174,"PHASE3":1176,"PHASE4":1178,"NA":1180},{"trials":1171,"activeCount":99},[],{"trials":1173,"activeCount":99},[],{"trials":1175,"activeCount":99},[],{"trials":1177,"activeCount":99},[],{"trials":1179,"activeCount":99},[],{"trials":1181,"activeCount":140,"soonestReadout":1186},[1182],{"nctId":1183,"briefTitle":1184,"status":133,"phases":1185,"primaryCompletion":1186,"completion":1186,"start":1187,"enrollment":1188,"conditions":1189,"interventions":1190},"NCT06333704","Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE",[],"2029-03-29","2023-03-10",4207,[15],[1168,1191,1192,1193],"SPIKEVAX Bivalent BA.4\u002F5","SPIKEVAX XBB.1.5","SPIKEVAX JN.1",{"intervention":1191,"totalTrials":140,"cells":1195},{"EARLY_PHASE1":1196,"PHASE1":1198,"PHASE2":1200,"PHASE3":1202,"PHASE4":1204,"NA":1206},{"trials":1197,"activeCount":99},[],{"trials":1199,"activeCount":99},[],{"trials":1201,"activeCount":99},[],{"trials":1203,"activeCount":99},[],{"trials":1205,"activeCount":99},[],{"trials":1207,"activeCount":140,"soonestReadout":1186},[1208],{"nctId":1183,"briefTitle":1184,"status":133,"phases":1209,"primaryCompletion":1186,"completion":1186,"start":1187,"enrollment":1188,"conditions":1210,"interventions":1211},[],[15],[1168,1191,1192,1193],{"intervention":1192,"totalTrials":140,"cells":1213},{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1218,"PHASE3":1220,"PHASE4":1222,"NA":1224},{"trials":1215,"activeCount":99},[],{"trials":1217,"activeCount":99},[],{"trials":1219,"activeCount":99},[],{"trials":1221,"activeCount":99},[],{"trials":1223,"activeCount":99},[],{"trials":1225,"activeCount":140,"soonestReadout":1186},[1226],{"nctId":1183,"briefTitle":1184,"status":133,"phases":1227,"primaryCompletion":1186,"completion":1186,"start":1187,"enrollment":1188,"conditions":1228,"interventions":1229},[],[15],[1168,1191,1192,1193],{"intervention":1193,"totalTrials":140,"cells":1231},{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1236,"PHASE3":1238,"PHASE4":1240,"NA":1242},{"trials":1233,"activeCount":99},[],{"trials":1235,"activeCount":99},[],{"trials":1237,"activeCount":99},[],{"trials":1239,"activeCount":99},[],{"trials":1241,"activeCount":99},[],{"trials":1243,"activeCount":140,"soonestReadout":1186},[1244],{"nctId":1183,"briefTitle":1184,"status":133,"phases":1245,"primaryCompletion":1186,"completion":1186,"start":1187,"enrollment":1188,"conditions":1246,"interventions":1247},[],[15],[1168,1191,1192,1193],{"intervention":1249,"totalTrials":140,"cells":1250},"mRNA-1273.712",{"EARLY_PHASE1":1251,"PHASE1":1253,"PHASE2":1255,"PHASE3":1257,"PHASE4":1259,"NA":1271},{"trials":1252,"activeCount":99},[],{"trials":1254,"activeCount":99},[],{"trials":1256,"activeCount":99},[],{"trials":1258,"activeCount":99},[],{"trials":1260,"activeCount":99},[1261],{"nctId":1262,"briefTitle":1263,"status":105,"phases":1264,"primaryCompletion":1265,"completion":1265,"start":1266,"enrollment":1267,"conditions":1268,"interventions":1270},"NCT06634797","A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age",[91],"2025-01-20","2024-10-08",1000,[1269],"Healthy Volunteers",[1249],{"trials":1272,"activeCount":99},[],{"intervention":209,"totalTrials":189,"cells":1274},{"EARLY_PHASE1":1275,"PHASE1":1277,"PHASE2":1287,"PHASE3":1343,"PHASE4":1387,"NA":1389},{"trials":1276,"activeCount":99},[],{"trials":1278,"activeCount":99},[1279,1283],{"nctId":200,"briefTitle":201,"status":105,"phases":1280,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":1281,"interventions":1282},[88],[15,23,20,207],[112,209,42,210,66],{"nctId":329,"briefTitle":330,"status":105,"phases":1284,"primaryCompletion":332,"completion":332,"start":333,"enrollment":334,"conditions":1285,"interventions":1286},[88],[15,18,336],[209,42,238,338,339],{"trials":1288,"activeCount":99},[1289,1303,1314,1324,1328,1339],{"nctId":1290,"briefTitle":1291,"status":105,"phases":1292,"primaryCompletion":1293,"completion":1293,"start":1294,"enrollment":1295,"conditions":1296,"interventions":1297},"NCT05827068","A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults",[88,89],"2023-11-20","2023-03-27",698,[23],[1298,1299,1300,209,1301,1302],"mRNA-1011.1","mRNA-1011.2","mRNA-1012.1","mRNA-1010.2","mRNA-1010.3",{"nctId":1304,"briefTitle":1305,"status":105,"phases":1306,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1309,"conditions":1310,"interventions":1311},"NCT05868382","Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults",[89],"2023-12-19","2023-05-15",270,[18],[209,1312,1313],"mRNA-1010.4","mRNA-1010.6",{"nctId":1315,"briefTitle":1316,"status":105,"phases":1317,"primaryCompletion":1318,"completion":1318,"start":1319,"enrollment":1320,"conditions":1321,"interventions":1322},"NCT04956575","A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults",[88,89],"2022-09-27","2021-07-06",885,[23],[209,1323],"Active Comparator",{"nctId":359,"briefTitle":360,"status":105,"phases":1325,"primaryCompletion":362,"completion":362,"start":363,"enrollment":364,"conditions":1326,"interventions":1327},[89],[18],[209,367,368,369,42,338],{"nctId":1329,"briefTitle":1330,"status":105,"phases":1331,"primaryCompletion":1332,"completion":1332,"start":1333,"enrollment":1334,"conditions":1335,"interventions":1336},"NCT05333289","A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults",[88,89],"2022-11-22","2022-04-06",572,[23],[1337,1338,209,1323],"mRNA-1030","mRNA-1020",{"nctId":218,"briefTitle":219,"status":105,"phases":1340,"primaryCompletion":221,"completion":221,"start":222,"enrollment":223,"conditions":1341,"interventions":1342},[88,89],[15,18],[226,209,112],{"trials":1344,"activeCount":99},[1345,1358,1368,1378],{"nctId":1346,"briefTitle":1347,"status":105,"phases":1348,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":1352,"interventions":1353},"NCT06602024","A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age",[90],"2025-08-21","2024-09-16",40817,[23],[209,1354,1355,1356,1357],"Fluarix®","Influsplit® Tetra","Fluarix Tetra","Alpharix® Tetra",{"nctId":1359,"briefTitle":1360,"status":105,"phases":1361,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":1364,"conditions":1365,"interventions":1366},"NCT05827978","Study of mRNA-1010 Seasonal Influenza Vaccine in Adults",[90],"2024-06-24","2023-04-17",8411,[23],[209,1367],"Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine",{"nctId":1369,"briefTitle":1370,"status":105,"phases":1371,"primaryCompletion":1372,"completion":1372,"start":1373,"enrollment":1374,"conditions":1375,"interventions":1376},"NCT05566639","A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older",[90],"2024-01-05","2022-09-14",22502,[23],[209,1377],"Fluarix Quadrivalent",{"nctId":1379,"briefTitle":1380,"status":105,"phases":1381,"primaryCompletion":1382,"completion":1382,"start":1383,"enrollment":1384,"conditions":1385,"interventions":1386},"NCT05415462","A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults",[90],"2023-09-04","2022-06-06",6102,[23],[209,1356],{"trials":1388,"activeCount":99},[],{"trials":1390,"activeCount":99},[],{"intervention":238,"totalTrials":27,"cells":1392},{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1401,"PHASE3":1412,"PHASE4":1439,"NA":1441},{"trials":1394,"activeCount":99},[],{"trials":1396,"activeCount":99},[1397],{"nctId":329,"briefTitle":330,"status":105,"phases":1398,"primaryCompletion":332,"completion":332,"start":333,"enrollment":334,"conditions":1399,"interventions":1400},[88],[15,18,336],[209,42,238,338,339],{"trials":1402,"activeCount":99},[1403],{"nctId":1404,"briefTitle":1405,"status":674,"phases":1406,"primaryCompletion":1407,"completion":1407,"start":1408,"enrollment":1409,"conditions":1410,"interventions":1411},"NCT05584202","Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants",[89],"2024-11-15","2022-09-30",68,[15],[238],{"trials":1413,"activeCount":99},[1414,1423,1427,1431,1435],{"nctId":1415,"briefTitle":1416,"status":105,"phases":1417,"primaryCompletion":1418,"completion":1418,"start":1419,"enrollment":1420,"conditions":1421,"interventions":1422},"NCT05436834","A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age",[90],"2025-10-20","2022-06-21",1807,[15],[238,261],{"nctId":230,"briefTitle":231,"status":105,"phases":1424,"primaryCompletion":233,"completion":233,"start":234,"enrollment":235,"conditions":1425,"interventions":1426},[89,90],[15],[112,238],{"nctId":400,"briefTitle":401,"status":105,"phases":1428,"primaryCompletion":403,"completion":403,"start":404,"enrollment":405,"conditions":1429,"interventions":1430},[90],[20],[42,408,238],{"nctId":248,"briefTitle":249,"status":105,"phases":1432,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":1433,"interventions":1434},[89,90],[15],[256,112,257,258,259,238,260,261,262],{"nctId":282,"briefTitle":283,"status":105,"phases":1436,"primaryCompletion":285,"completion":285,"start":286,"enrollment":287,"conditions":1437,"interventions":1438},[89,90],[15],[259,112,238],{"trials":1440,"activeCount":99},[],{"trials":1442,"activeCount":99},[],{"intervention":1444,"totalTrials":33,"cells":1445},"mRNA-1083",{"EARLY_PHASE1":1446,"PHASE1":1448,"PHASE2":1450,"PHASE3":1481,"PHASE4":1505,"NA":1507},{"trials":1447,"activeCount":99},[],{"trials":1449,"activeCount":99},[],{"trials":1451,"activeCount":99},[1452,1472],{"nctId":1453,"briefTitle":1454,"status":105,"phases":1455,"primaryCompletion":1456,"completion":1456,"start":1457,"enrollment":1458,"conditions":1459,"interventions":1460},"NCT05827926","A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults",[88,89],"2024-12-03","2023-04-14",1758,[15,18],[1461,1462,1463,1464,1465,1466,1467,1468,1469,1444,1470,1471],"Influenza Vaccine 1","mRNA-1083.1","mRNA-1083.2","mRNA-1083.3","Investigational Influenza Vaccine 1","Investigational COVID-19 Vaccine 1","COVID-19 Vaccine 1","Investigational Influenza Vaccine 2","Influenza Vaccine 2","Investigational COVID-19 Vaccine 2","COVID-19 Vaccine 2",{"nctId":1473,"briefTitle":1474,"status":105,"phases":1475,"primaryCompletion":1476,"completion":1476,"start":1477,"enrollment":1478,"conditions":1479,"interventions":1480},"NCT06508320","A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)",[89],"2025-09-25","2024-07-15",932,[18,15],[1444],{"trials":1482,"activeCount":99},[1483,1494],{"nctId":1484,"briefTitle":1485,"status":105,"phases":1486,"primaryCompletion":1487,"completion":1487,"start":1488,"enrollment":1489,"conditions":1490,"interventions":1491},"NCT06097273","A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age",[90],"2024-05-28","2023-10-19",8061,[15,18],[1444,1492,1493],"Influenza Vaccine","COVID-19 Vaccine",{"nctId":1495,"briefTitle":1496,"status":105,"phases":1497,"primaryCompletion":1498,"completion":1498,"start":1499,"enrollment":1500,"conditions":1501,"interventions":1502},"NCT06694389","Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age",[90],"2025-11-17","2024-11-18",2457,[29,18],[1444,1503,1504],"Licensed Influenza Vaccine","SARS-CoV-2 Vaccine",{"trials":1506,"activeCount":99},[],{"trials":1508,"activeCount":99},[],{"intervention":261,"totalTrials":36,"cells":1510},{"EARLY_PHASE1":1511,"PHASE1":1513,"PHASE2":1515,"PHASE3":1517,"PHASE4":1538,"NA":1540},{"trials":1512,"activeCount":99},[],{"trials":1514,"activeCount":99},[],{"trials":1516,"activeCount":99},[],{"trials":1518,"activeCount":99},[1519,1523,1534],{"nctId":1415,"briefTitle":1416,"status":105,"phases":1520,"primaryCompletion":1418,"completion":1418,"start":1419,"enrollment":1420,"conditions":1521,"interventions":1522},[90],[15],[238,261],{"nctId":1524,"briefTitle":1525,"status":105,"phases":1526,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":1529,"conditions":1530,"interventions":1531},"NCT05815498","A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19",[90],"2025-04-12","2023-03-28",13553,[29],[1532,260,1533,261],"mRNA-1283.222","mRNA-1283.815",{"nctId":248,"briefTitle":249,"status":105,"phases":1535,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":1536,"interventions":1537},[89,90],[15],[256,112,257,258,259,238,260,261,262],{"trials":1539,"activeCount":99},[],{"trials":1541,"activeCount":99},[],{"intervention":260,"totalTrials":36,"cells":1543},{"EARLY_PHASE1":1544,"PHASE1":1546,"PHASE2":1548,"PHASE3":1550,"PHASE4":1564,"NA":1566},{"trials":1545,"activeCount":99},[],{"trials":1547,"activeCount":99},[],{"trials":1549,"activeCount":99},[],{"trials":1551,"activeCount":99},[1552,1556,1560],{"nctId":1524,"briefTitle":1525,"status":105,"phases":1553,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":1529,"conditions":1554,"interventions":1555},[90],[29],[1532,260,1533,261],{"nctId":248,"briefTitle":249,"status":105,"phases":1557,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":1558,"interventions":1559},[89,90],[15],[256,112,257,258,259,238,260,261,262],{"nctId":264,"briefTitle":265,"status":105,"phases":1561,"primaryCompletion":267,"completion":267,"start":268,"enrollment":269,"conditions":1562,"interventions":1563},[89,90],[15],[112,260],{"trials":1565,"activeCount":99},[],{"trials":1567,"activeCount":99},[],{"intervention":1492,"totalTrials":439,"cells":1569},{"EARLY_PHASE1":1570,"PHASE1":1572,"PHASE2":1574,"PHASE3":1596,"PHASE4":1602,"NA":1604},{"trials":1571,"activeCount":99},[],{"trials":1573,"activeCount":99},[],{"trials":1575,"activeCount":99},[1576],{"nctId":1577,"briefTitle":1578,"status":105,"phases":1579,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":1583,"interventions":1584},"NCT06864143","A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to \u003C65 Years of Age",[89],"2025-10-13","2025-03-07",1320,[18,15],[1585,1586,1587,1588,1589,1590,1591,1592,1492,1493,1593,1594,1595],"mRNA-1083 Composition 1 Dose A Lot A","mRNA-1083 Composition 1 Dose A Lot B","mRNA-1083 Composition 1 Dose B","mRNA-1083 Composition 1 Dose C","mRNA-1083 Composition 2 Dose A","mRNA-1083 Composition 2 Dose B","mRNA-1083 Composition 3 Dose A","mRNA-1083 Composition 3 Dose B","Investigational Influenza Vaccine","Investigational COVID-19 Vaccine Lot A","Investigational COVID-19 Vaccine Lot B",{"trials":1597,"activeCount":99},[1598],{"nctId":1484,"briefTitle":1485,"status":105,"phases":1599,"primaryCompletion":1487,"completion":1487,"start":1488,"enrollment":1489,"conditions":1600,"interventions":1601},[90],[15,18],[1444,1492,1493],{"trials":1603,"activeCount":99},[],{"trials":1605,"activeCount":99},[],{"intervention":1356,"totalTrials":439,"cells":1607},{"EARLY_PHASE1":1608,"PHASE1":1610,"PHASE2":1612,"PHASE3":1614,"PHASE4":1624,"NA":1626},{"trials":1609,"activeCount":99},[],{"trials":1611,"activeCount":99},[],{"trials":1613,"activeCount":99},[],{"trials":1615,"activeCount":99},[1616,1620],{"nctId":1346,"briefTitle":1347,"status":105,"phases":1617,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":1618,"interventions":1619},[90],[23],[209,1354,1355,1356,1357],{"nctId":1379,"briefTitle":1380,"status":105,"phases":1621,"primaryCompletion":1382,"completion":1382,"start":1383,"enrollment":1384,"conditions":1622,"interventions":1623},[90],[23],[209,1356],{"trials":1625,"activeCount":99},[],{"trials":1627,"activeCount":99},[],{"intervention":259,"totalTrials":439,"cells":1629},{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1634,"PHASE3":1636,"PHASE4":1646,"NA":1648},{"trials":1631,"activeCount":99},[],{"trials":1633,"activeCount":99},[],{"trials":1635,"activeCount":99},[],{"trials":1637,"activeCount":99},[1638,1642],{"nctId":248,"briefTitle":249,"status":105,"phases":1639,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":1640,"interventions":1641},[89,90],[15],[256,112,257,258,259,238,260,261,262],{"nctId":282,"briefTitle":283,"status":105,"phases":1643,"primaryCompletion":285,"completion":285,"start":286,"enrollment":287,"conditions":1644,"interventions":1645},[89,90],[15],[259,112,238],{"trials":1647,"activeCount":99},[],{"trials":1649,"activeCount":99},[],{"intervention":1651,"totalTrials":140,"cells":1652},"Investigational mRNA-1273.815",{"EARLY_PHASE1":1653,"PHASE1":1655,"PHASE2":1657,"PHASE3":1659,"PHASE4":1671,"NA":1673},{"trials":1654,"activeCount":99},[],{"trials":1656,"activeCount":99},[],{"trials":1658,"activeCount":99},[],{"trials":1660,"activeCount":99},[1661],{"nctId":1662,"briefTitle":1663,"status":105,"phases":1664,"primaryCompletion":1665,"completion":1665,"start":1666,"enrollment":1667,"conditions":1668,"interventions":1669},"NCT06354998","A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults",[90],"2024-05-10","2024-04-08",217,[15],[1651,1670],"Licensed Spikevax Vaccine",{"trials":1672,"activeCount":99},[],{"trials":1674,"activeCount":99},[],{"intervention":1670,"totalTrials":140,"cells":1676},{"EARLY_PHASE1":1677,"PHASE1":1679,"PHASE2":1681,"PHASE3":1683,"PHASE4":1689,"NA":1691},{"trials":1678,"activeCount":99},[],{"trials":1680,"activeCount":99},[],{"trials":1682,"activeCount":99},[],{"trials":1684,"activeCount":99},[1685],{"nctId":1662,"briefTitle":1663,"status":105,"phases":1686,"primaryCompletion":1665,"completion":1665,"start":1666,"enrollment":1667,"conditions":1687,"interventions":1688},[90],[15],[1651,1670],{"trials":1690,"activeCount":99},[],{"trials":1692,"activeCount":99},[],{"intervention":1354,"totalTrials":140,"cells":1694},{"EARLY_PHASE1":1695,"PHASE1":1697,"PHASE2":1699,"PHASE3":1701,"PHASE4":1707,"NA":1709},{"trials":1696,"activeCount":99},[],{"trials":1698,"activeCount":99},[],{"trials":1700,"activeCount":99},[],{"trials":1702,"activeCount":99},[1703],{"nctId":1346,"briefTitle":1347,"status":105,"phases":1704,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":1705,"interventions":1706},[90],[23],[209,1354,1355,1356,1357],{"trials":1708,"activeCount":99},[],{"trials":1710,"activeCount":99},[],{"intervention":1355,"totalTrials":140,"cells":1712},{"EARLY_PHASE1":1713,"PHASE1":1715,"PHASE2":1717,"PHASE3":1719,"PHASE4":1725,"NA":1727},{"trials":1714,"activeCount":99},[],{"trials":1716,"activeCount":99},[],{"trials":1718,"activeCount":99},[],{"trials":1720,"activeCount":99},[1721],{"nctId":1346,"briefTitle":1347,"status":105,"phases":1722,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":1723,"interventions":1724},[90],[23],[209,1354,1355,1356,1357],{"trials":1726,"activeCount":99},[],{"trials":1728,"activeCount":99},[],{"intervention":1357,"totalTrials":140,"cells":1730},{"EARLY_PHASE1":1731,"PHASE1":1733,"PHASE2":1735,"PHASE3":1737,"PHASE4":1743,"NA":1745},{"trials":1732,"activeCount":99},[],{"trials":1734,"activeCount":99},[],{"trials":1736,"activeCount":99},[],{"trials":1738,"activeCount":99},[1739],{"nctId":1346,"briefTitle":1347,"status":105,"phases":1740,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":1741,"interventions":1742},[90],[23],[209,1354,1355,1356,1357],{"trials":1744,"activeCount":99},[],{"trials":1746,"activeCount":99},[],{"intervention":1367,"totalTrials":140,"cells":1748},{"EARLY_PHASE1":1749,"PHASE1":1751,"PHASE2":1753,"PHASE3":1755,"PHASE4":1761,"NA":1763},{"trials":1750,"activeCount":99},[],{"trials":1752,"activeCount":99},[],{"trials":1754,"activeCount":99},[],{"trials":1756,"activeCount":99},[1757],{"nctId":1359,"briefTitle":1360,"status":105,"phases":1758,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":1364,"conditions":1759,"interventions":1760},[90],[23],[209,1367],{"trials":1762,"activeCount":99},[],{"trials":1764,"activeCount":99},[],{"intervention":1532,"totalTrials":140,"cells":1766},{"EARLY_PHASE1":1767,"PHASE1":1769,"PHASE2":1771,"PHASE3":1773,"PHASE4":1779,"NA":1781},{"trials":1768,"activeCount":99},[],{"trials":1770,"activeCount":99},[],{"trials":1772,"activeCount":99},[],{"trials":1774,"activeCount":99},[1775],{"nctId":1524,"briefTitle":1525,"status":105,"phases":1776,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":1529,"conditions":1777,"interventions":1778},[90],[29],[1532,260,1533,261],{"trials":1780,"activeCount":99},[],{"trials":1782,"activeCount":99},[],{"intervention":1533,"totalTrials":140,"cells":1784},{"EARLY_PHASE1":1785,"PHASE1":1787,"PHASE2":1789,"PHASE3":1791,"PHASE4":1797,"NA":1799},{"trials":1786,"activeCount":99},[],{"trials":1788,"activeCount":99},[],{"trials":1790,"activeCount":99},[],{"trials":1792,"activeCount":99},[1793],{"nctId":1524,"briefTitle":1525,"status":105,"phases":1794,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":1529,"conditions":1795,"interventions":1796},[90],[29],[1532,260,1533,261],{"trials":1798,"activeCount":99},[],{"trials":1800,"activeCount":99},[],{"intervention":1503,"totalTrials":140,"cells":1802},{"EARLY_PHASE1":1803,"PHASE1":1805,"PHASE2":1807,"PHASE3":1809,"PHASE4":1815,"NA":1817},{"trials":1804,"activeCount":99},[],{"trials":1806,"activeCount":99},[],{"trials":1808,"activeCount":99},[],{"trials":1810,"activeCount":99},[1811],{"nctId":1495,"briefTitle":1496,"status":105,"phases":1812,"primaryCompletion":1498,"completion":1498,"start":1499,"enrollment":1500,"conditions":1813,"interventions":1814},[90],[29,18],[1444,1503,1504],{"trials":1816,"activeCount":99},[],{"trials":1818,"activeCount":99},[],{"intervention":1504,"totalTrials":140,"cells":1820},{"EARLY_PHASE1":1821,"PHASE1":1823,"PHASE2":1825,"PHASE3":1827,"PHASE4":1833,"NA":1835},{"trials":1822,"activeCount":99},[],{"trials":1824,"activeCount":99},[],{"trials":1826,"activeCount":99},[],{"trials":1828,"activeCount":99},[1829],{"nctId":1495,"briefTitle":1496,"status":105,"phases":1830,"primaryCompletion":1498,"completion":1498,"start":1499,"enrollment":1500,"conditions":1831,"interventions":1832},[90],[29,18],[1444,1503,1504],{"trials":1834,"activeCount":99},[],{"trials":1836,"activeCount":99},[],{"intervention":408,"totalTrials":140,"cells":1838},{"EARLY_PHASE1":1839,"PHASE1":1841,"PHASE2":1843,"PHASE3":1845,"PHASE4":1851,"NA":1853},{"trials":1840,"activeCount":99},[],{"trials":1842,"activeCount":99},[],{"trials":1844,"activeCount":99},[],{"trials":1846,"activeCount":99},[1847],{"nctId":400,"briefTitle":401,"status":105,"phases":1848,"primaryCompletion":403,"completion":403,"start":404,"enrollment":405,"conditions":1849,"interventions":1850},[90],[20],[42,408,238],{"trials":1852,"activeCount":99},[],{"trials":1854,"activeCount":99},[],{"intervention":256,"totalTrials":140,"cells":1856},{"EARLY_PHASE1":1857,"PHASE1":1859,"PHASE2":1861,"PHASE3":1863,"PHASE4":1869,"NA":1871},{"trials":1858,"activeCount":99},[],{"trials":1860,"activeCount":99},[],{"trials":1862,"activeCount":99},[],{"trials":1864,"activeCount":99},[1865],{"nctId":248,"briefTitle":249,"status":105,"phases":1866,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":1867,"interventions":1868},[89,90],[15],[256,112,257,258,259,238,260,261,262],{"trials":1870,"activeCount":99},[],{"trials":1872,"activeCount":99},[],{"intervention":257,"totalTrials":140,"cells":1874},{"EARLY_PHASE1":1875,"PHASE1":1877,"PHASE2":1879,"PHASE3":1881,"PHASE4":1887,"NA":1889},{"trials":1876,"activeCount":99},[],{"trials":1878,"activeCount":99},[],{"trials":1880,"activeCount":99},[],{"trials":1882,"activeCount":99},[1883],{"nctId":248,"briefTitle":249,"status":105,"phases":1884,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":1885,"interventions":1886},[89,90],[15],[256,112,257,258,259,238,260,261,262],{"trials":1888,"activeCount":99},[],{"trials":1890,"activeCount":99},[],{"intervention":258,"totalTrials":140,"cells":1892},{"EARLY_PHASE1":1893,"PHASE1":1895,"PHASE2":1897,"PHASE3":1899,"PHASE4":1905,"NA":1907},{"trials":1894,"activeCount":99},[],{"trials":1896,"activeCount":99},[],{"trials":1898,"activeCount":99},[],{"trials":1900,"activeCount":99},[1901],{"nctId":248,"briefTitle":249,"status":105,"phases":1902,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":1903,"interventions":1904},[89,90],[15],[256,112,257,258,259,238,260,261,262],{"trials":1906,"activeCount":99},[],{"trials":1908,"activeCount":99},[],{"intervention":262,"totalTrials":140,"cells":1910},{"EARLY_PHASE1":1911,"PHASE1":1913,"PHASE2":1915,"PHASE3":1917,"PHASE4":1923,"NA":1925},{"trials":1912,"activeCount":99},[],{"trials":1914,"activeCount":99},[],{"trials":1916,"activeCount":99},[],{"trials":1918,"activeCount":99},[1919],{"nctId":248,"briefTitle":249,"status":105,"phases":1920,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":1921,"interventions":1922},[89,90],[15],[256,112,257,258,259,238,260,261,262],{"trials":1924,"activeCount":99},[],{"trials":1926,"activeCount":99},[],{"intervention":1377,"totalTrials":140,"cells":1928},{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1933,"PHASE3":1935,"PHASE4":1941,"NA":1943},{"trials":1930,"activeCount":99},[],{"trials":1932,"activeCount":99},[],{"trials":1934,"activeCount":99},[],{"trials":1936,"activeCount":99},[1937],{"nctId":1369,"briefTitle":1370,"status":105,"phases":1938,"primaryCompletion":1372,"completion":1372,"start":1373,"enrollment":1374,"conditions":1939,"interventions":1940},[90],[23],[209,1377],{"trials":1942,"activeCount":99},[],{"trials":1944,"activeCount":99},[],{"intervention":424,"totalTrials":140,"cells":1946},{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1953,"PHASE4":1959,"NA":1961},{"trials":1948,"activeCount":99},[],{"trials":1950,"activeCount":99},[],{"trials":1952,"activeCount":99},[],{"trials":1954,"activeCount":99},[1955],{"nctId":416,"briefTitle":417,"status":105,"phases":1956,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":1957,"interventions":1958},[90],[20],[42,424],{"trials":1960,"activeCount":99},[],{"trials":1962,"activeCount":99},[],{"intervention":1964,"totalTrials":439,"cells":1965},"Durvalumab",{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1982,"PHASE3":1996,"PHASE4":1998,"NA":2000},{"trials":1967,"activeCount":99},[],{"trials":1969,"activeCount":99},[1970],{"nctId":1971,"briefTitle":1972,"status":105,"phases":1973,"primaryCompletion":1974,"completion":1974,"start":1975,"enrollment":1976,"conditions":1977,"interventions":1980},"NCT03739931","Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies",[88],"2025-08-01","2018-11-27",134,[1978,1979],"Dose Escalation: Relapsed\u002FRefractory Solid Tumor Malignancies or Lymphoma","Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma",[1981,1964],"mRNA-2752",{"trials":1983,"activeCount":99},[1984],{"nctId":1985,"briefTitle":1986,"status":674,"phases":1987,"primaryCompletion":1988,"completion":1988,"start":1989,"enrollment":1990,"conditions":1991,"interventions":1994},"NCT03323398","Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies",[88,89],"2021-08-18","2017-08-15",79,[1992,1993],"Relapsed\u002FRefractory Solid Tumor Malignancies or Lymphoma","Ovarian Cancer",[1995,1964],"mRNA-2416",{"trials":1997,"activeCount":99},[],{"trials":1999,"activeCount":99},[],{"trials":2001,"activeCount":99},[],{"intervention":2003,"totalTrials":439,"cells":2004},"mRNA-1893",{"EARLY_PHASE1":2005,"PHASE1":2007,"PHASE2":2017,"PHASE3":2028,"PHASE4":2030,"NA":2032},{"trials":2006,"activeCount":99},[],{"trials":2008,"activeCount":99},[2009],{"nctId":2010,"briefTitle":2011,"status":105,"phases":2012,"primaryCompletion":2013,"completion":2013,"start":2014,"enrollment":568,"conditions":2015,"interventions":2016},"NCT04064905","Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults",[88],"2021-03-22","2019-07-30",[35],[2003],{"trials":2018,"activeCount":99},[2019],{"nctId":2020,"briefTitle":2021,"status":105,"phases":2022,"primaryCompletion":2023,"completion":2023,"start":2024,"enrollment":2025,"conditions":2026,"interventions":2027},"NCT04917861","A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas",[89],"2024-07-26","2021-06-07",808,[35],[2003],{"trials":2029,"activeCount":99},[],{"trials":2031,"activeCount":99},[],{"trials":2033,"activeCount":99},[],{"intervention":1323,"totalTrials":439,"cells":2035},{"EARLY_PHASE1":2036,"PHASE1":2038,"PHASE2":2040,"PHASE3":2050,"PHASE4":2052,"NA":2054},{"trials":2037,"activeCount":99},[],{"trials":2039,"activeCount":99},[],{"trials":2041,"activeCount":99},[2042,2046],{"nctId":1315,"briefTitle":1316,"status":105,"phases":2043,"primaryCompletion":1318,"completion":1318,"start":1319,"enrollment":1320,"conditions":2044,"interventions":2045},[88,89],[23],[209,1323],{"nctId":1329,"briefTitle":1330,"status":105,"phases":2047,"primaryCompletion":1332,"completion":1332,"start":1333,"enrollment":1334,"conditions":2048,"interventions":2049},[88,89],[23],[1337,1338,209,1323],{"trials":2051,"activeCount":99},[],{"trials":2053,"activeCount":99},[],{"trials":2055,"activeCount":99},[],{"intervention":338,"totalTrials":439,"cells":2057},{"EARLY_PHASE1":2058,"PHASE1":2060,"PHASE2":2066,"PHASE3":2072,"PHASE4":2074,"NA":2076},{"trials":2059,"activeCount":99},[],{"trials":2061,"activeCount":99},[2062],{"nctId":329,"briefTitle":330,"status":105,"phases":2063,"primaryCompletion":332,"completion":332,"start":333,"enrollment":334,"conditions":2064,"interventions":2065},[88],[15,18,336],[209,42,238,338,339],{"trials":2067,"activeCount":99},[2068],{"nctId":359,"briefTitle":360,"status":105,"phases":2069,"primaryCompletion":362,"completion":362,"start":363,"enrollment":364,"conditions":2070,"interventions":2071},[89],[18],[209,367,368,369,42,338],{"trials":2073,"activeCount":99},[],{"trials":2075,"activeCount":99},[],{"trials":2077,"activeCount":99},[],{"intervention":1995,"totalTrials":140,"cells":2079},{"EARLY_PHASE1":2080,"PHASE1":2082,"PHASE2":2084,"PHASE3":2090,"PHASE4":2092,"NA":2094},{"trials":2081,"activeCount":99},[],{"trials":2083,"activeCount":99},[],{"trials":2085,"activeCount":99},[2086],{"nctId":1985,"briefTitle":1986,"status":674,"phases":2087,"primaryCompletion":1988,"completion":1988,"start":1989,"enrollment":1990,"conditions":2088,"interventions":2089},[88,89],[1992,1993],[1995,1964],{"trials":2091,"activeCount":99},[],{"trials":2093,"activeCount":99},[],{"trials":2095,"activeCount":99},[],{"intervention":788,"totalTrials":140,"cells":2097},{"EARLY_PHASE1":2098,"PHASE1":2100,"PHASE2":2102,"PHASE3":2108,"PHASE4":2110,"NA":2112},{"trials":2099,"activeCount":99},[],{"trials":2101,"activeCount":99},[],{"trials":2103,"activeCount":99},[2104],{"nctId":779,"briefTitle":780,"status":105,"phases":2105,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":2106,"interventions":2107},[88,89],[786],[788,770],{"trials":2109,"activeCount":99},[],{"trials":2111,"activeCount":99},[],{"trials":2113,"activeCount":99},[],{"intervention":1461,"totalTrials":140,"cells":2115},{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2120,"PHASE3":2126,"PHASE4":2128,"NA":2130},{"trials":2117,"activeCount":99},[],{"trials":2119,"activeCount":99},[],{"trials":2121,"activeCount":99},[2122],{"nctId":1453,"briefTitle":1454,"status":105,"phases":2123,"primaryCompletion":1456,"completion":1456,"start":1457,"enrollment":1458,"conditions":2124,"interventions":2125},[88,89],[15,18],[1461,1462,1463,1464,1465,1466,1467,1468,1469,1444,1470,1471],{"trials":2127,"activeCount":99},[],{"trials":2129,"activeCount":99},[],{"trials":2131,"activeCount":99},[],{"intervention":1462,"totalTrials":140,"cells":2133},{"EARLY_PHASE1":2134,"PHASE1":2136,"PHASE2":2138,"PHASE3":2144,"PHASE4":2146,"NA":2148},{"trials":2135,"activeCount":99},[],{"trials":2137,"activeCount":99},[],{"trials":2139,"activeCount":99},[2140],{"nctId":1453,"briefTitle":1454,"status":105,"phases":2141,"primaryCompletion":1456,"completion":1456,"start":1457,"enrollment":1458,"conditions":2142,"interventions":2143},[88,89],[15,18],[1461,1462,1463,1464,1465,1466,1467,1468,1469,1444,1470,1471],{"trials":2145,"activeCount":99},[],{"trials":2147,"activeCount":99},[],{"trials":2149,"activeCount":99},[],{"intervention":1463,"totalTrials":140,"cells":2151},{"EARLY_PHASE1":2152,"PHASE1":2154,"PHASE2":2156,"PHASE3":2162,"PHASE4":2164,"NA":2166},{"trials":2153,"activeCount":99},[],{"trials":2155,"activeCount":99},[],{"trials":2157,"activeCount":99},[2158],{"nctId":1453,"briefTitle":1454,"status":105,"phases":2159,"primaryCompletion":1456,"completion":1456,"start":1457,"enrollment":1458,"conditions":2160,"interventions":2161},[88,89],[15,18],[1461,1462,1463,1464,1465,1466,1467,1468,1469,1444,1470,1471],{"trials":2163,"activeCount":99},[],{"trials":2165,"activeCount":99},[],{"trials":2167,"activeCount":99},[],{"intervention":1464,"totalTrials":140,"cells":2169},{"EARLY_PHASE1":2170,"PHASE1":2172,"PHASE2":2174,"PHASE3":2180,"PHASE4":2182,"NA":2184},{"trials":2171,"activeCount":99},[],{"trials":2173,"activeCount":99},[],{"trials":2175,"activeCount":99},[2176],{"nctId":1453,"briefTitle":1454,"status":105,"phases":2177,"primaryCompletion":1456,"completion":1456,"start":1457,"enrollment":1458,"conditions":2178,"interventions":2179},[88,89],[15,18],[1461,1462,1463,1464,1465,1466,1467,1468,1469,1444,1470,1471],{"trials":2181,"activeCount":99},[],{"trials":2183,"activeCount":99},[],{"trials":2185,"activeCount":99},[],{"intervention":1465,"totalTrials":140,"cells":2187},{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2198,"PHASE4":2200,"NA":2202},{"trials":2189,"activeCount":99},[],{"trials":2191,"activeCount":99},[],{"trials":2193,"activeCount":99},[2194],{"nctId":1453,"briefTitle":1454,"status":105,"phases":2195,"primaryCompletion":1456,"completion":1456,"start":1457,"enrollment":1458,"conditions":2196,"interventions":2197},[88,89],[15,18],[1461,1462,1463,1464,1465,1466,1467,1468,1469,1444,1470,1471],{"trials":2199,"activeCount":99},[],{"trials":2201,"activeCount":99},[],{"trials":2203,"activeCount":99},[],{"intervention":1466,"totalTrials":140,"cells":2205},{"EARLY_PHASE1":2206,"PHASE1":2208,"PHASE2":2210,"PHASE3":2216,"PHASE4":2218,"NA":2220},{"trials":2207,"activeCount":99},[],{"trials":2209,"activeCount":99},[],{"trials":2211,"activeCount":99},[2212],{"nctId":1453,"briefTitle":1454,"status":105,"phases":2213,"primaryCompletion":1456,"completion":1456,"start":1457,"enrollment":1458,"conditions":2214,"interventions":2215},[88,89],[15,18],[1461,1462,1463,1464,1465,1466,1467,1468,1469,1444,1470,1471],{"trials":2217,"activeCount":99},[],{"trials":2219,"activeCount":99},[],{"trials":2221,"activeCount":99},[],{"intervention":1467,"totalTrials":140,"cells":2223},{"EARLY_PHASE1":2224,"PHASE1":2226,"PHASE2":2228,"PHASE3":2234,"PHASE4":2236,"NA":2238},{"trials":2225,"activeCount":99},[],{"trials":2227,"activeCount":99},[],{"trials":2229,"activeCount":99},[2230],{"nctId":1453,"briefTitle":1454,"status":105,"phases":2231,"primaryCompletion":1456,"completion":1456,"start":1457,"enrollment":1458,"conditions":2232,"interventions":2233},[88,89],[15,18],[1461,1462,1463,1464,1465,1466,1467,1468,1469,1444,1470,1471],{"trials":2235,"activeCount":99},[],{"trials":2237,"activeCount":99},[],{"trials":2239,"activeCount":99},[],{"intervention":1468,"totalTrials":140,"cells":2241},{"EARLY_PHASE1":2242,"PHASE1":2244,"PHASE2":2246,"PHASE3":2252,"PHASE4":2254,"NA":2256},{"trials":2243,"activeCount":99},[],{"trials":2245,"activeCount":99},[],{"trials":2247,"activeCount":99},[2248],{"nctId":1453,"briefTitle":1454,"status":105,"phases":2249,"primaryCompletion":1456,"completion":1456,"start":1457,"enrollment":1458,"conditions":2250,"interventions":2251},[88,89],[15,18],[1461,1462,1463,1464,1465,1466,1467,1468,1469,1444,1470,1471],{"trials":2253,"activeCount":99},[],{"trials":2255,"activeCount":99},[],{"trials":2257,"activeCount":99},[],{"intervention":1469,"totalTrials":140,"cells":2259},{"EARLY_PHASE1":2260,"PHASE1":2262,"PHASE2":2264,"PHASE3":2270,"PHASE4":2272,"NA":2274},{"trials":2261,"activeCount":99},[],{"trials":2263,"activeCount":99},[],{"trials":2265,"activeCount":99},[2266],{"nctId":1453,"briefTitle":1454,"status":105,"phases":2267,"primaryCompletion":1456,"completion":1456,"start":1457,"enrollment":1458,"conditions":2268,"interventions":2269},[88,89],[15,18],[1461,1462,1463,1464,1465,1466,1467,1468,1469,1444,1470,1471],{"trials":2271,"activeCount":99},[],{"trials":2273,"activeCount":99},[],{"trials":2275,"activeCount":99},[],{"intervention":1470,"totalTrials":140,"cells":2277},{"EARLY_PHASE1":2278,"PHASE1":2280,"PHASE2":2282,"PHASE3":2288,"PHASE4":2290,"NA":2292},{"trials":2279,"activeCount":99},[],{"trials":2281,"activeCount":99},[],{"trials":2283,"activeCount":99},[2284],{"nctId":1453,"briefTitle":1454,"status":105,"phases":2285,"primaryCompletion":1456,"completion":1456,"start":1457,"enrollment":1458,"conditions":2286,"interventions":2287},[88,89],[15,18],[1461,1462,1463,1464,1465,1466,1467,1468,1469,1444,1470,1471],{"trials":2289,"activeCount":99},[],{"trials":2291,"activeCount":99},[],{"trials":2293,"activeCount":99},[],{"intervention":1471,"totalTrials":140,"cells":2295},{"EARLY_PHASE1":2296,"PHASE1":2298,"PHASE2":2300,"PHASE3":2306,"PHASE4":2308,"NA":2310},{"trials":2297,"activeCount":99},[],{"trials":2299,"activeCount":99},[],{"trials":2301,"activeCount":99},[2302],{"nctId":1453,"briefTitle":1454,"status":105,"phases":2303,"primaryCompletion":1456,"completion":1456,"start":1457,"enrollment":1458,"conditions":2304,"interventions":2305},[88,89],[15,18],[1461,1462,1463,1464,1465,1466,1467,1468,1469,1444,1470,1471],{"trials":2307,"activeCount":99},[],{"trials":2309,"activeCount":99},[],{"trials":2311,"activeCount":99},[],{"intervention":1298,"totalTrials":140,"cells":2313},{"EARLY_PHASE1":2314,"PHASE1":2316,"PHASE2":2318,"PHASE3":2324,"PHASE4":2326,"NA":2328},{"trials":2315,"activeCount":99},[],{"trials":2317,"activeCount":99},[],{"trials":2319,"activeCount":99},[2320],{"nctId":1290,"briefTitle":1291,"status":105,"phases":2321,"primaryCompletion":1293,"completion":1293,"start":1294,"enrollment":1295,"conditions":2322,"interventions":2323},[88,89],[23],[1298,1299,1300,209,1301,1302],{"trials":2325,"activeCount":99},[],{"trials":2327,"activeCount":99},[],{"trials":2329,"activeCount":99},[],{"intervention":1299,"totalTrials":140,"cells":2331},{"EARLY_PHASE1":2332,"PHASE1":2334,"PHASE2":2336,"PHASE3":2342,"PHASE4":2344,"NA":2346},{"trials":2333,"activeCount":99},[],{"trials":2335,"activeCount":99},[],{"trials":2337,"activeCount":99},[2338],{"nctId":1290,"briefTitle":1291,"status":105,"phases":2339,"primaryCompletion":1293,"completion":1293,"start":1294,"enrollment":1295,"conditions":2340,"interventions":2341},[88,89],[23],[1298,1299,1300,209,1301,1302],{"trials":2343,"activeCount":99},[],{"trials":2345,"activeCount":99},[],{"trials":2347,"activeCount":99},[],{"intervention":1300,"totalTrials":140,"cells":2349},{"EARLY_PHASE1":2350,"PHASE1":2352,"PHASE2":2354,"PHASE3":2360,"PHASE4":2362,"NA":2364},{"trials":2351,"activeCount":99},[],{"trials":2353,"activeCount":99},[],{"trials":2355,"activeCount":99},[2356],{"nctId":1290,"briefTitle":1291,"status":105,"phases":2357,"primaryCompletion":1293,"completion":1293,"start":1294,"enrollment":1295,"conditions":2358,"interventions":2359},[88,89],[23],[1298,1299,1300,209,1301,1302],{"trials":2361,"activeCount":99},[],{"trials":2363,"activeCount":99},[],{"trials":2365,"activeCount":99},[],{"intervention":1301,"totalTrials":140,"cells":2367},{"EARLY_PHASE1":2368,"PHASE1":2370,"PHASE2":2372,"PHASE3":2378,"PHASE4":2380,"NA":2382},{"trials":2369,"activeCount":99},[],{"trials":2371,"activeCount":99},[],{"trials":2373,"activeCount":99},[2374],{"nctId":1290,"briefTitle":1291,"status":105,"phases":2375,"primaryCompletion":1293,"completion":1293,"start":1294,"enrollment":1295,"conditions":2376,"interventions":2377},[88,89],[23],[1298,1299,1300,209,1301,1302],{"trials":2379,"activeCount":99},[],{"trials":2381,"activeCount":99},[],{"trials":2383,"activeCount":99},[],{"intervention":1302,"totalTrials":140,"cells":2385},{"EARLY_PHASE1":2386,"PHASE1":2388,"PHASE2":2390,"PHASE3":2396,"PHASE4":2398,"NA":2400},{"trials":2387,"activeCount":99},[],{"trials":2389,"activeCount":99},[],{"trials":2391,"activeCount":99},[2392],{"nctId":1290,"briefTitle":1291,"status":105,"phases":2393,"primaryCompletion":1293,"completion":1293,"start":1294,"enrollment":1295,"conditions":2394,"interventions":2395},[88,89],[23],[1298,1299,1300,209,1301,1302],{"trials":2397,"activeCount":99},[],{"trials":2399,"activeCount":99},[],{"trials":2401,"activeCount":99},[],{"intervention":2403,"totalTrials":140,"cells":2404},"mRNA-1769",{"EARLY_PHASE1":2405,"PHASE1":2407,"PHASE2":2409,"PHASE3":2422,"PHASE4":2424,"NA":2426},{"trials":2406,"activeCount":99},[],{"trials":2408,"activeCount":99},[],{"trials":2410,"activeCount":99},[2411],{"nctId":2412,"briefTitle":2413,"status":105,"phases":2414,"primaryCompletion":2415,"completion":2415,"start":2416,"enrollment":2417,"conditions":2418,"interventions":2421},"NCT05995275","A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to \u003C50 Years of Age",[88,89],"2025-07-08","2023-08-15",351,[2419,2420],"Smallpox","Mpox",[2403],{"trials":2423,"activeCount":99},[],{"trials":2425,"activeCount":99},[],{"trials":2427,"activeCount":99},[],{"intervention":1312,"totalTrials":140,"cells":2429},{"EARLY_PHASE1":2430,"PHASE1":2432,"PHASE2":2434,"PHASE3":2440,"PHASE4":2442,"NA":2444},{"trials":2431,"activeCount":99},[],{"trials":2433,"activeCount":99},[],{"trials":2435,"activeCount":99},[2436],{"nctId":1304,"briefTitle":1305,"status":105,"phases":2437,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1309,"conditions":2438,"interventions":2439},[89],[18],[209,1312,1313],{"trials":2441,"activeCount":99},[],{"trials":2443,"activeCount":99},[],{"trials":2445,"activeCount":99},[],{"intervention":1313,"totalTrials":140,"cells":2447},{"EARLY_PHASE1":2448,"PHASE1":2450,"PHASE2":2452,"PHASE3":2458,"PHASE4":2460,"NA":2462},{"trials":2449,"activeCount":99},[],{"trials":2451,"activeCount":99},[],{"trials":2453,"activeCount":99},[2454],{"nctId":1304,"briefTitle":1305,"status":105,"phases":2455,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1309,"conditions":2456,"interventions":2457},[89],[18],[209,1312,1313],{"trials":2459,"activeCount":99},[],{"trials":2461,"activeCount":99},[],{"trials":2463,"activeCount":99},[],{"intervention":124,"totalTrials":140,"cells":2465},{"EARLY_PHASE1":2466,"PHASE1":2468,"PHASE2":2470,"PHASE3":2476,"PHASE4":2478,"NA":2480},{"trials":2467,"activeCount":99},[],{"trials":2469,"activeCount":99},[],{"trials":2471,"activeCount":99},[2472],{"nctId":116,"briefTitle":117,"status":105,"phases":2473,"primaryCompletion":119,"completion":119,"start":120,"enrollment":121,"conditions":2474,"interventions":2475},[89],[15],[95,124,112,125],{"trials":2477,"activeCount":99},[],{"trials":2479,"activeCount":99},[],{"trials":2481,"activeCount":99},[],{"intervention":125,"totalTrials":140,"cells":2483},{"EARLY_PHASE1":2484,"PHASE1":2486,"PHASE2":2488,"PHASE3":2494,"PHASE4":2496,"NA":2498},{"trials":2485,"activeCount":99},[],{"trials":2487,"activeCount":99},[],{"trials":2489,"activeCount":99},[2490],{"nctId":116,"briefTitle":117,"status":105,"phases":2491,"primaryCompletion":119,"completion":119,"start":120,"enrollment":121,"conditions":2492,"interventions":2493},[89],[15],[95,124,112,125],{"trials":2495,"activeCount":99},[],{"trials":2497,"activeCount":99},[],{"trials":2499,"activeCount":99},[],{"intervention":2501,"totalTrials":140,"cells":2502},"Biological: mRNA-1273",{"EARLY_PHASE1":2503,"PHASE1":2505,"PHASE2":2507,"PHASE3":2519,"PHASE4":2521,"NA":2523},{"trials":2504,"activeCount":99},[],{"trials":2506,"activeCount":99},[],{"trials":2508,"activeCount":99},[2509],{"nctId":2510,"briefTitle":2511,"status":105,"phases":2512,"primaryCompletion":2513,"completion":2513,"start":2514,"enrollment":2515,"conditions":2516,"interventions":2517},"NCT04405076","Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older",[89],"2021-10-28","2020-05-29",660,[15],[2501,2518],"mRNA-1273.351",{"trials":2520,"activeCount":99},[],{"trials":2522,"activeCount":99},[],{"trials":2524,"activeCount":99},[],{"intervention":2518,"totalTrials":140,"cells":2526},{"EARLY_PHASE1":2527,"PHASE1":2529,"PHASE2":2531,"PHASE3":2537,"PHASE4":2539,"NA":2541},{"trials":2528,"activeCount":99},[],{"trials":2530,"activeCount":99},[],{"trials":2532,"activeCount":99},[2533],{"nctId":2510,"briefTitle":2511,"status":105,"phases":2534,"primaryCompletion":2513,"completion":2513,"start":2514,"enrollment":2515,"conditions":2535,"interventions":2536},[89],[15],[2501,2518],{"trials":2538,"activeCount":99},[],{"trials":2540,"activeCount":99},[],{"trials":2542,"activeCount":99},[],{"intervention":367,"totalTrials":140,"cells":2544},{"EARLY_PHASE1":2545,"PHASE1":2547,"PHASE2":2549,"PHASE3":2555,"PHASE4":2557,"NA":2559},{"trials":2546,"activeCount":99},[],{"trials":2548,"activeCount":99},[],{"trials":2550,"activeCount":99},[2551],{"nctId":359,"briefTitle":360,"status":105,"phases":2552,"primaryCompletion":362,"completion":362,"start":363,"enrollment":364,"conditions":2553,"interventions":2554},[89],[18],[209,367,368,369,42,338],{"trials":2556,"activeCount":99},[],{"trials":2558,"activeCount":99},[],{"trials":2560,"activeCount":99},[],{"intervention":368,"totalTrials":140,"cells":2562},{"EARLY_PHASE1":2563,"PHASE1":2565,"PHASE2":2567,"PHASE3":2573,"PHASE4":2575,"NA":2577},{"trials":2564,"activeCount":99},[],{"trials":2566,"activeCount":99},[],{"trials":2568,"activeCount":99},[2569],{"nctId":359,"briefTitle":360,"status":105,"phases":2570,"primaryCompletion":362,"completion":362,"start":363,"enrollment":364,"conditions":2571,"interventions":2572},[89],[18],[209,367,368,369,42,338],{"trials":2574,"activeCount":99},[],{"trials":2576,"activeCount":99},[],{"trials":2578,"activeCount":99},[],{"intervention":369,"totalTrials":140,"cells":2580},{"EARLY_PHASE1":2581,"PHASE1":2583,"PHASE2":2585,"PHASE3":2591,"PHASE4":2593,"NA":2595},{"trials":2582,"activeCount":99},[],{"trials":2584,"activeCount":99},[],{"trials":2586,"activeCount":99},[2587],{"nctId":359,"briefTitle":360,"status":105,"phases":2588,"primaryCompletion":362,"completion":362,"start":363,"enrollment":364,"conditions":2589,"interventions":2590},[89],[18],[209,367,368,369,42,338],{"trials":2592,"activeCount":99},[],{"trials":2594,"activeCount":99},[],{"trials":2596,"activeCount":99},[],{"intervention":1337,"totalTrials":140,"cells":2598},{"EARLY_PHASE1":2599,"PHASE1":2601,"PHASE2":2603,"PHASE3":2609,"PHASE4":2611,"NA":2613},{"trials":2600,"activeCount":99},[],{"trials":2602,"activeCount":99},[],{"trials":2604,"activeCount":99},[2605],{"nctId":1329,"briefTitle":1330,"status":105,"phases":2606,"primaryCompletion":1332,"completion":1332,"start":1333,"enrollment":1334,"conditions":2607,"interventions":2608},[88,89],[23],[1337,1338,209,1323],{"trials":2610,"activeCount":99},[],{"trials":2612,"activeCount":99},[],{"trials":2614,"activeCount":99},[],{"intervention":1338,"totalTrials":140,"cells":2616},{"EARLY_PHASE1":2617,"PHASE1":2619,"PHASE2":2621,"PHASE3":2627,"PHASE4":2629,"NA":2631},{"trials":2618,"activeCount":99},[],{"trials":2620,"activeCount":99},[],{"trials":2622,"activeCount":99},[2623],{"nctId":1329,"briefTitle":1330,"status":105,"phases":2624,"primaryCompletion":1332,"completion":1332,"start":1333,"enrollment":1334,"conditions":2625,"interventions":2626},[88,89],[23],[1337,1338,209,1323],{"trials":2628,"activeCount":99},[],{"trials":2630,"activeCount":99},[],{"trials":2632,"activeCount":99},[],{"intervention":2634,"totalTrials":140,"cells":2635},"mRNA-3704",{"EARLY_PHASE1":2636,"PHASE1":2638,"PHASE2":2640,"PHASE3":2652,"PHASE4":2654,"NA":2656},{"trials":2637,"activeCount":99},[],{"trials":2639,"activeCount":99},[],{"trials":2641,"activeCount":99},[2642],{"nctId":2643,"briefTitle":2644,"status":639,"phases":2645,"primaryCompletion":2646,"completion":2646,"start":2647,"enrollment":99,"conditions":2648,"interventions":2651},"NCT03810690","Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia",[88,89],"2020-08-18","2019-05-28",[2649,2650],"Methylmalonic Acidemia (MMA)","Metabolism, Inborn Errors",[2634],{"trials":2653,"activeCount":99},[],{"trials":2655,"activeCount":99},[],{"trials":2657,"activeCount":99},[],{"intervention":2659,"totalTrials":140,"cells":2660},"mRNA-3210",{"EARLY_PHASE1":2661,"PHASE1":2663,"PHASE2":2665,"PHASE3":2677,"PHASE4":2679,"NA":2681},{"trials":2662,"activeCount":99},[],{"trials":2664,"activeCount":99},[],{"trials":2666,"activeCount":99},[2667],{"nctId":2668,"briefTitle":2669,"status":639,"phases":2670,"primaryCompletion":2671,"completion":2672,"start":2673,"enrollment":99,"conditions":2674,"interventions":2676},"NCT06147856","A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria",[88,89],"2026-08-10","2027-08-05","2024-03-29",[2675],"Phenylketonuria",[2659],{"trials":2678,"activeCount":99},[],{"trials":2680,"activeCount":99},[],{"trials":2682,"activeCount":99},[],{"intervention":226,"totalTrials":140,"cells":2684},{"EARLY_PHASE1":2685,"PHASE1":2687,"PHASE2":2689,"PHASE3":2695,"PHASE4":2697,"NA":2699},{"trials":2686,"activeCount":99},[],{"trials":2688,"activeCount":99},[],{"trials":2690,"activeCount":99},[2691],{"nctId":218,"briefTitle":219,"status":105,"phases":2692,"primaryCompletion":221,"completion":221,"start":222,"enrollment":223,"conditions":2693,"interventions":2694},[88,89],[15,18],[226,209,112],{"trials":2696,"activeCount":99},[],{"trials":2698,"activeCount":99},[],{"trials":2700,"activeCount":99},[],{"intervention":1585,"totalTrials":140,"cells":2702},{"EARLY_PHASE1":2703,"PHASE1":2705,"PHASE2":2707,"PHASE3":2713,"PHASE4":2715,"NA":2717},{"trials":2704,"activeCount":99},[],{"trials":2706,"activeCount":99},[],{"trials":2708,"activeCount":99},[2709],{"nctId":1577,"briefTitle":1578,"status":105,"phases":2710,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":2711,"interventions":2712},[89],[18,15],[1585,1586,1587,1588,1589,1590,1591,1592,1492,1493,1593,1594,1595],{"trials":2714,"activeCount":99},[],{"trials":2716,"activeCount":99},[],{"trials":2718,"activeCount":99},[],{"intervention":1586,"totalTrials":140,"cells":2720},{"EARLY_PHASE1":2721,"PHASE1":2723,"PHASE2":2725,"PHASE3":2731,"PHASE4":2733,"NA":2735},{"trials":2722,"activeCount":99},[],{"trials":2724,"activeCount":99},[],{"trials":2726,"activeCount":99},[2727],{"nctId":1577,"briefTitle":1578,"status":105,"phases":2728,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":2729,"interventions":2730},[89],[18,15],[1585,1586,1587,1588,1589,1590,1591,1592,1492,1493,1593,1594,1595],{"trials":2732,"activeCount":99},[],{"trials":2734,"activeCount":99},[],{"trials":2736,"activeCount":99},[],{"intervention":1587,"totalTrials":140,"cells":2738},{"EARLY_PHASE1":2739,"PHASE1":2741,"PHASE2":2743,"PHASE3":2749,"PHASE4":2751,"NA":2753},{"trials":2740,"activeCount":99},[],{"trials":2742,"activeCount":99},[],{"trials":2744,"activeCount":99},[2745],{"nctId":1577,"briefTitle":1578,"status":105,"phases":2746,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":2747,"interventions":2748},[89],[18,15],[1585,1586,1587,1588,1589,1590,1591,1592,1492,1493,1593,1594,1595],{"trials":2750,"activeCount":99},[],{"trials":2752,"activeCount":99},[],{"trials":2754,"activeCount":99},[],{"intervention":1588,"totalTrials":140,"cells":2756},{"EARLY_PHASE1":2757,"PHASE1":2759,"PHASE2":2761,"PHASE3":2767,"PHASE4":2769,"NA":2771},{"trials":2758,"activeCount":99},[],{"trials":2760,"activeCount":99},[],{"trials":2762,"activeCount":99},[2763],{"nctId":1577,"briefTitle":1578,"status":105,"phases":2764,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":2765,"interventions":2766},[89],[18,15],[1585,1586,1587,1588,1589,1590,1591,1592,1492,1493,1593,1594,1595],{"trials":2768,"activeCount":99},[],{"trials":2770,"activeCount":99},[],{"trials":2772,"activeCount":99},[],{"intervention":1589,"totalTrials":140,"cells":2774},{"EARLY_PHASE1":2775,"PHASE1":2777,"PHASE2":2779,"PHASE3":2785,"PHASE4":2787,"NA":2789},{"trials":2776,"activeCount":99},[],{"trials":2778,"activeCount":99},[],{"trials":2780,"activeCount":99},[2781],{"nctId":1577,"briefTitle":1578,"status":105,"phases":2782,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":2783,"interventions":2784},[89],[18,15],[1585,1586,1587,1588,1589,1590,1591,1592,1492,1493,1593,1594,1595],{"trials":2786,"activeCount":99},[],{"trials":2788,"activeCount":99},[],{"trials":2790,"activeCount":99},[],{"intervention":1590,"totalTrials":140,"cells":2792},{"EARLY_PHASE1":2793,"PHASE1":2795,"PHASE2":2797,"PHASE3":2803,"PHASE4":2805,"NA":2807},{"trials":2794,"activeCount":99},[],{"trials":2796,"activeCount":99},[],{"trials":2798,"activeCount":99},[2799],{"nctId":1577,"briefTitle":1578,"status":105,"phases":2800,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":2801,"interventions":2802},[89],[18,15],[1585,1586,1587,1588,1589,1590,1591,1592,1492,1493,1593,1594,1595],{"trials":2804,"activeCount":99},[],{"trials":2806,"activeCount":99},[],{"trials":2808,"activeCount":99},[],{"intervention":1591,"totalTrials":140,"cells":2810},{"EARLY_PHASE1":2811,"PHASE1":2813,"PHASE2":2815,"PHASE3":2821,"PHASE4":2823,"NA":2825},{"trials":2812,"activeCount":99},[],{"trials":2814,"activeCount":99},[],{"trials":2816,"activeCount":99},[2817],{"nctId":1577,"briefTitle":1578,"status":105,"phases":2818,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":2819,"interventions":2820},[89],[18,15],[1585,1586,1587,1588,1589,1590,1591,1592,1492,1493,1593,1594,1595],{"trials":2822,"activeCount":99},[],{"trials":2824,"activeCount":99},[],{"trials":2826,"activeCount":99},[],{"intervention":1592,"totalTrials":140,"cells":2828},{"EARLY_PHASE1":2829,"PHASE1":2831,"PHASE2":2833,"PHASE3":2839,"PHASE4":2841,"NA":2843},{"trials":2830,"activeCount":99},[],{"trials":2832,"activeCount":99},[],{"trials":2834,"activeCount":99},[2835],{"nctId":1577,"briefTitle":1578,"status":105,"phases":2836,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":2837,"interventions":2838},[89],[18,15],[1585,1586,1587,1588,1589,1590,1591,1592,1492,1493,1593,1594,1595],{"trials":2840,"activeCount":99},[],{"trials":2842,"activeCount":99},[],{"trials":2844,"activeCount":99},[],{"intervention":1593,"totalTrials":140,"cells":2846},{"EARLY_PHASE1":2847,"PHASE1":2849,"PHASE2":2851,"PHASE3":2857,"PHASE4":2859,"NA":2861},{"trials":2848,"activeCount":99},[],{"trials":2850,"activeCount":99},[],{"trials":2852,"activeCount":99},[2853],{"nctId":1577,"briefTitle":1578,"status":105,"phases":2854,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":2855,"interventions":2856},[89],[18,15],[1585,1586,1587,1588,1589,1590,1591,1592,1492,1493,1593,1594,1595],{"trials":2858,"activeCount":99},[],{"trials":2860,"activeCount":99},[],{"trials":2862,"activeCount":99},[],{"intervention":1594,"totalTrials":140,"cells":2864},{"EARLY_PHASE1":2865,"PHASE1":2867,"PHASE2":2869,"PHASE3":2875,"PHASE4":2877,"NA":2879},{"trials":2866,"activeCount":99},[],{"trials":2868,"activeCount":99},[],{"trials":2870,"activeCount":99},[2871],{"nctId":1577,"briefTitle":1578,"status":105,"phases":2872,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":2873,"interventions":2874},[89],[18,15],[1585,1586,1587,1588,1589,1590,1591,1592,1492,1493,1593,1594,1595],{"trials":2876,"activeCount":99},[],{"trials":2878,"activeCount":99},[],{"trials":2880,"activeCount":99},[],{"intervention":1595,"totalTrials":140,"cells":2882},{"EARLY_PHASE1":2883,"PHASE1":2885,"PHASE2":2887,"PHASE3":2893,"PHASE4":2895,"NA":2897},{"trials":2884,"activeCount":99},[],{"trials":2886,"activeCount":99},[],{"trials":2888,"activeCount":99},[2889],{"nctId":1577,"briefTitle":1578,"status":105,"phases":2890,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":2891,"interventions":2892},[89],[18,15],[1585,1586,1587,1588,1589,1590,1591,1592,1492,1493,1593,1594,1595],{"trials":2894,"activeCount":99},[],{"trials":2896,"activeCount":99},[],{"trials":2898,"activeCount":99},[],{"intervention":2900,"totalTrials":140,"cells":2901},"mRNA-1018 for H5N8",{"EARLY_PHASE1":2902,"PHASE1":2904,"PHASE2":2906,"PHASE3":2921,"PHASE4":2923,"NA":2925},{"trials":2903,"activeCount":99},[],{"trials":2905,"activeCount":99},[],{"trials":2907,"activeCount":99},[2908],{"nctId":2909,"briefTitle":2910,"status":105,"phases":2911,"primaryCompletion":2912,"completion":2912,"start":2913,"enrollment":2914,"conditions":2915,"interventions":2916},"NCT05972174","A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults",[88,89],"2024-07-16","2023-07-10",1504,[18],[2900,2917,2918,2919,2920],"mRNA-1018 for H7N9","mRNA-1018 for H5 Only","mRNA-1018 for H7 Only","mRNA-1018 for H5 Only-CG",{"trials":2922,"activeCount":99},[],{"trials":2924,"activeCount":99},[],{"trials":2926,"activeCount":99},[],{"intervention":2917,"totalTrials":140,"cells":2928},{"EARLY_PHASE1":2929,"PHASE1":2931,"PHASE2":2933,"PHASE3":2939,"PHASE4":2941,"NA":2943},{"trials":2930,"activeCount":99},[],{"trials":2932,"activeCount":99},[],{"trials":2934,"activeCount":99},[2935],{"nctId":2909,"briefTitle":2910,"status":105,"phases":2936,"primaryCompletion":2912,"completion":2912,"start":2913,"enrollment":2914,"conditions":2937,"interventions":2938},[88,89],[18],[2900,2917,2918,2919,2920],{"trials":2940,"activeCount":99},[],{"trials":2942,"activeCount":99},[],{"trials":2944,"activeCount":99},[],{"intervention":2918,"totalTrials":140,"cells":2946},{"EARLY_PHASE1":2947,"PHASE1":2949,"PHASE2":2951,"PHASE3":2957,"PHASE4":2959,"NA":2961},{"trials":2948,"activeCount":99},[],{"trials":2950,"activeCount":99},[],{"trials":2952,"activeCount":99},[2953],{"nctId":2909,"briefTitle":2910,"status":105,"phases":2954,"primaryCompletion":2912,"completion":2912,"start":2913,"enrollment":2914,"conditions":2955,"interventions":2956},[88,89],[18],[2900,2917,2918,2919,2920],{"trials":2958,"activeCount":99},[],{"trials":2960,"activeCount":99},[],{"trials":2962,"activeCount":99},[],{"intervention":2919,"totalTrials":140,"cells":2964},{"EARLY_PHASE1":2965,"PHASE1":2967,"PHASE2":2969,"PHASE3":2975,"PHASE4":2977,"NA":2979},{"trials":2966,"activeCount":99},[],{"trials":2968,"activeCount":99},[],{"trials":2970,"activeCount":99},[2971],{"nctId":2909,"briefTitle":2910,"status":105,"phases":2972,"primaryCompletion":2912,"completion":2912,"start":2913,"enrollment":2914,"conditions":2973,"interventions":2974},[88,89],[18],[2900,2917,2918,2919,2920],{"trials":2976,"activeCount":99},[],{"trials":2978,"activeCount":99},[],{"trials":2980,"activeCount":99},[],{"intervention":2920,"totalTrials":140,"cells":2982},{"EARLY_PHASE1":2983,"PHASE1":2985,"PHASE2":2987,"PHASE3":2993,"PHASE4":2995,"NA":2997},{"trials":2984,"activeCount":99},[],{"trials":2986,"activeCount":99},[],{"trials":2988,"activeCount":99},[2989],{"nctId":2909,"briefTitle":2910,"status":105,"phases":2990,"primaryCompletion":2912,"completion":2912,"start":2913,"enrollment":2914,"conditions":2991,"interventions":2992},[88,89],[18],[2900,2917,2918,2919,2920],{"trials":2994,"activeCount":99},[],{"trials":2996,"activeCount":99},[],{"trials":2998,"activeCount":99},[],{"intervention":3000,"totalTrials":140,"cells":3001},"mRNA-1608",{"EARLY_PHASE1":3002,"PHASE1":3004,"PHASE2":3006,"PHASE3":3019,"PHASE4":3021,"NA":3023},{"trials":3003,"activeCount":99},[],{"trials":3005,"activeCount":99},[],{"trials":3007,"activeCount":99},[3008],{"nctId":3009,"briefTitle":3010,"status":105,"phases":3011,"primaryCompletion":3012,"completion":3012,"start":3013,"enrollment":3014,"conditions":3015,"interventions":3017},"NCT06033261","A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes",[88,89],"2025-04-25","2023-09-06",303,[3016],"Genital Herpes",[3000,3018],"BEXSERO",{"trials":3020,"activeCount":99},[],{"trials":3022,"activeCount":99},[],{"trials":3024,"activeCount":99},[],{"intervention":3018,"totalTrials":140,"cells":3026},{"EARLY_PHASE1":3027,"PHASE1":3029,"PHASE2":3031,"PHASE3":3037,"PHASE4":3039,"NA":3041},{"trials":3028,"activeCount":99},[],{"trials":3030,"activeCount":99},[],{"trials":3032,"activeCount":99},[3033],{"nctId":3009,"briefTitle":3010,"status":105,"phases":3034,"primaryCompletion":3012,"completion":3012,"start":3013,"enrollment":3014,"conditions":3035,"interventions":3036},[88,89],[3016],[3000,3018],{"trials":3038,"activeCount":99},[],{"trials":3040,"activeCount":99},[],{"trials":3042,"activeCount":99},[],{"intervention":3044,"totalTrials":439,"cells":3045},"mRNA-1653",{"EARLY_PHASE1":3046,"PHASE1":3048,"PHASE2":3069,"PHASE3":3071,"PHASE4":3073,"NA":3075},{"trials":3047,"activeCount":99},[],{"trials":3049,"activeCount":99},[3050,3060],{"nctId":3051,"briefTitle":3052,"status":105,"phases":3053,"primaryCompletion":3054,"completion":3054,"start":3055,"enrollment":3056,"conditions":3057,"interventions":3059},"NCT04144348","Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure",[88],"2022-12-20","2019-11-04",51,[3058],"Human Metapneumovirus and Human Parainfluenza Infection",[3044],{"nctId":3061,"briefTitle":3062,"status":105,"phases":3063,"primaryCompletion":3064,"completion":3064,"start":3065,"enrollment":3066,"conditions":3067,"interventions":3068},"NCT03392389","Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults",[88],"2019-07-29","2017-12-04",124,[3058],[3044],{"trials":3070,"activeCount":99},[],{"trials":3072,"activeCount":99},[],{"trials":3074,"activeCount":99},[],{"trials":3076,"activeCount":99},[],{"intervention":3078,"totalTrials":140,"cells":3079},"mRNA-1944",{"EARLY_PHASE1":3080,"PHASE1":3082,"PHASE2":3093,"PHASE3":3095,"PHASE4":3097,"NA":3099},{"trials":3081,"activeCount":99},[],{"trials":3083,"activeCount":99},[3084],{"nctId":3085,"briefTitle":3086,"status":105,"phases":3087,"primaryCompletion":2024,"completion":2024,"start":3088,"enrollment":3089,"conditions":3090,"interventions":3092},"NCT03829384","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults",[88],"2019-01-22",39,[3091],"Prevention of Chikungunya Virus Infection",[3078],{"trials":3094,"activeCount":99},[],{"trials":3096,"activeCount":99},[],{"trials":3098,"activeCount":99},[],{"trials":3100,"activeCount":99},[],{"intervention":3102,"totalTrials":140,"cells":3103},"VAL-181388",{"EARLY_PHASE1":3104,"PHASE1":3106,"PHASE2":3118,"PHASE3":3120,"PHASE4":3122,"NA":3124},{"trials":3105,"activeCount":99},[],{"trials":3107,"activeCount":99},[3108],{"nctId":3109,"briefTitle":3110,"status":105,"phases":3111,"primaryCompletion":3112,"completion":3112,"start":3113,"enrollment":3114,"conditions":3115,"interventions":3117},"NCT03325075","Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants",[88],"2019-03-19","2017-07-19",60,[3116],"Chikungunya Virus",[3102],{"trials":3119,"activeCount":99},[],{"trials":3121,"activeCount":99},[],{"trials":3123,"activeCount":99},[],{"trials":3125,"activeCount":99},[],{"intervention":3127,"totalTrials":140,"cells":3128},"mRNA-6231",{"EARLY_PHASE1":3129,"PHASE1":3131,"PHASE2":3141,"PHASE3":3143,"PHASE4":3145,"NA":3147},{"trials":3130,"activeCount":99},[],{"trials":3132,"activeCount":99},[3133],{"nctId":3134,"briefTitle":3135,"status":105,"phases":3136,"primaryCompletion":3137,"completion":3137,"start":3138,"enrollment":819,"conditions":3139,"interventions":3140},"NCT04916431","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults",[88],"2022-08-02","2021-07-28",[1269],[3127],{"trials":3142,"activeCount":99},[],{"trials":3144,"activeCount":99},[],{"trials":3146,"activeCount":99},[],{"trials":3148,"activeCount":99},[],{"intervention":210,"totalTrials":140,"cells":3150},{"EARLY_PHASE1":3151,"PHASE1":3153,"PHASE2":3159,"PHASE3":3161,"PHASE4":3163,"NA":3165},{"trials":3152,"activeCount":99},[],{"trials":3154,"activeCount":99},[3155],{"nctId":200,"briefTitle":201,"status":105,"phases":3156,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":3157,"interventions":3158},[88],[15,23,20,207],[112,209,42,210,66],{"trials":3160,"activeCount":99},[],{"trials":3162,"activeCount":99},[],{"trials":3164,"activeCount":99},[],{"trials":3166,"activeCount":99},[],{"intervention":3168,"totalTrials":140,"cells":3169},"VAL-339851",{"EARLY_PHASE1":3170,"PHASE1":3172,"PHASE2":3183,"PHASE3":3185,"PHASE4":3187,"NA":3189},{"trials":3171,"activeCount":99},[],{"trials":3173,"activeCount":99},[3174],{"nctId":3175,"briefTitle":3176,"status":105,"phases":3177,"primaryCompletion":3178,"completion":3178,"start":3179,"enrollment":3180,"conditions":3181,"interventions":3182},"NCT03345043","Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects",[88],"2018-08-13","2016-05-11",156,[18],[3168],{"trials":3184,"activeCount":99},[],{"trials":3186,"activeCount":99},[],{"trials":3188,"activeCount":99},[],{"trials":3190,"activeCount":99},[],{"intervention":1981,"totalTrials":140,"cells":3192},{"EARLY_PHASE1":3193,"PHASE1":3195,"PHASE2":3201,"PHASE3":3203,"PHASE4":3205,"NA":3207},{"trials":3194,"activeCount":99},[],{"trials":3196,"activeCount":99},[3197],{"nctId":1971,"briefTitle":1972,"status":105,"phases":3198,"primaryCompletion":1974,"completion":1974,"start":1975,"enrollment":1976,"conditions":3199,"interventions":3200},[88],[1978,1979],[1981,1964],{"trials":3202,"activeCount":99},[],{"trials":3204,"activeCount":99},[],{"trials":3206,"activeCount":99},[],{"trials":3208,"activeCount":99},[],{"intervention":3210,"totalTrials":140,"cells":3211},"mRNA-1325",{"EARLY_PHASE1":3212,"PHASE1":3214,"PHASE2":3225,"PHASE3":3227,"PHASE4":3229,"NA":3231},{"trials":3213,"activeCount":99},[],{"trials":3215,"activeCount":99},[3216],{"nctId":3217,"briefTitle":3218,"status":105,"phases":3219,"primaryCompletion":3220,"completion":3220,"start":3221,"enrollment":3222,"conditions":3223,"interventions":3224},"NCT03014089","Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects",[88],"2019-07-31","2016-12-21",90,[35],[3210],{"trials":3226,"activeCount":99},[],{"trials":3228,"activeCount":99},[],{"trials":3230,"activeCount":99},[],{"trials":3232,"activeCount":99},[],{"intervention":3234,"totalTrials":140,"cells":3235},"VAL-506440",{"EARLY_PHASE1":3236,"PHASE1":3238,"PHASE2":3249,"PHASE3":3251,"PHASE4":3253,"NA":3255},{"trials":3237,"activeCount":99},[],{"trials":3239,"activeCount":99},[3240],{"nctId":3241,"briefTitle":3242,"status":105,"phases":3243,"primaryCompletion":3244,"completion":3244,"start":3245,"enrollment":3246,"conditions":3247,"interventions":3248},"NCT03076385","Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects",[88],"2018-10","2015-12",201,[18],[3234],{"trials":3250,"activeCount":99},[],{"trials":3252,"activeCount":99},[],{"trials":3254,"activeCount":99},[],{"trials":3256,"activeCount":99},[],{"intervention":624,"totalTrials":140,"cells":3258},{"EARLY_PHASE1":3259,"PHASE1":3261,"PHASE2":3267,"PHASE3":3269,"PHASE4":3271,"NA":3273},{"trials":3260,"activeCount":99},[],{"trials":3262,"activeCount":99},[3263],{"nctId":616,"briefTitle":617,"status":105,"phases":3264,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":3265,"interventions":3266},[88],[26],[66,624],{"trials":3268,"activeCount":99},[],{"trials":3270,"activeCount":99},[],{"trials":3272,"activeCount":99},[],{"trials":3274,"activeCount":99},[],{"intervention":3276,"totalTrials":140,"cells":3277},"mRNA-2736",{"EARLY_PHASE1":3278,"PHASE1":3280,"PHASE2":3288,"PHASE3":3290,"PHASE4":3292,"NA":3294},{"trials":3279,"activeCount":99},[],{"trials":3281,"activeCount":99},[3282],{"nctId":3283,"briefTitle":3284,"status":639,"phases":3285,"primaryCompletion":41,"completion":41,"start":2416,"enrollment":99,"conditions":3286,"interventions":3287},"NCT05918250","mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)",[88],[856],[3276],{"trials":3289,"activeCount":99},[],{"trials":3291,"activeCount":99},[],{"trials":3293,"activeCount":99},[],{"trials":3295,"activeCount":99},[],{"intervention":339,"totalTrials":140,"cells":3297},{"EARLY_PHASE1":3298,"PHASE1":3300,"PHASE2":3306,"PHASE3":3308,"PHASE4":3310,"NA":3312},{"trials":3299,"activeCount":99},[],{"trials":3301,"activeCount":99},[3302],{"nctId":329,"briefTitle":330,"status":105,"phases":3303,"primaryCompletion":332,"completion":332,"start":333,"enrollment":334,"conditions":3304,"interventions":3305},[88],[15,18,336],[209,42,238,338,339],{"trials":3307,"activeCount":99},[],{"trials":3309,"activeCount":99},[],{"trials":3311,"activeCount":99},[],{"trials":3313,"activeCount":99},[],{"intervention":1493,"totalTrials":36,"cells":3315},{"EARLY_PHASE1":3316,"PHASE1":3318,"PHASE2":3320,"PHASE3":3326,"PHASE4":3332,"NA":3334},{"trials":3317,"activeCount":99},[],{"trials":3319,"activeCount":99},[],{"trials":3321,"activeCount":99},[3322],{"nctId":1577,"briefTitle":1578,"status":105,"phases":3323,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":3324,"interventions":3325},[89],[18,15],[1585,1586,1587,1588,1589,1590,1591,1592,1492,1493,1593,1594,1595],{"trials":3327,"activeCount":99},[3328],{"nctId":1484,"briefTitle":1485,"status":105,"phases":3329,"primaryCompletion":1487,"completion":1487,"start":1488,"enrollment":1489,"conditions":3330,"interventions":3331},[90],[15,18],[1444,1492,1493],{"trials":3333,"activeCount":99},[],{"trials":3335,"activeCount":99},[3336],{"nctId":3337,"briefTitle":3338,"status":105,"phases":3339,"primaryCompletion":3340,"completion":3340,"start":3341,"enrollment":3342,"conditions":3343,"interventions":3345},"NCT04941144","Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination",[],"2023-04-28","2021-12-22",8538,[3344],"Coronavirus Disease (COVID-19)",[1493],{"intervention":3347,"totalTrials":140,"cells":3348},"Moderna COVID-19 Vaccine",{"EARLY_PHASE1":3349,"PHASE1":3351,"PHASE2":3353,"PHASE3":3355,"PHASE4":3357,"NA":3359},{"trials":3350,"activeCount":99},[],{"trials":3352,"activeCount":99},[],{"trials":3354,"activeCount":99},[],{"trials":3356,"activeCount":99},[],{"trials":3358,"activeCount":99},[],{"trials":3360,"activeCount":99},[3361],{"nctId":3362,"briefTitle":3363,"status":105,"phases":3364,"primaryCompletion":3365,"completion":3365,"start":3366,"enrollment":3367,"conditions":3368,"interventions":3369},"NCT05765578","An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4\u002FBA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)",[],"2024-06-17","2023-03-08",1713,[29],[3347,3370,3371,3372,3373],"Moderna mRNA1273.222 Booster","Pfizer COVID-19 Vaccine","Moderna 2023 Updated COVID-19 vaccine","Pfizer 2023 Updated COVID-19 vaccine",{"intervention":3370,"totalTrials":140,"cells":3375},{"EARLY_PHASE1":3376,"PHASE1":3378,"PHASE2":3380,"PHASE3":3382,"PHASE4":3384,"NA":3386},{"trials":3377,"activeCount":99},[],{"trials":3379,"activeCount":99},[],{"trials":3381,"activeCount":99},[],{"trials":3383,"activeCount":99},[],{"trials":3385,"activeCount":99},[],{"trials":3387,"activeCount":99},[3388],{"nctId":3362,"briefTitle":3363,"status":105,"phases":3389,"primaryCompletion":3365,"completion":3365,"start":3366,"enrollment":3367,"conditions":3390,"interventions":3391},[],[29],[3347,3370,3371,3372,3373],{"intervention":3371,"totalTrials":140,"cells":3393},{"EARLY_PHASE1":3394,"PHASE1":3396,"PHASE2":3398,"PHASE3":3400,"PHASE4":3402,"NA":3404},{"trials":3395,"activeCount":99},[],{"trials":3397,"activeCount":99},[],{"trials":3399,"activeCount":99},[],{"trials":3401,"activeCount":99},[],{"trials":3403,"activeCount":99},[],{"trials":3405,"activeCount":99},[3406],{"nctId":3362,"briefTitle":3363,"status":105,"phases":3407,"primaryCompletion":3365,"completion":3365,"start":3366,"enrollment":3367,"conditions":3408,"interventions":3409},[],[29],[3347,3370,3371,3372,3373],{"intervention":3372,"totalTrials":140,"cells":3411},{"EARLY_PHASE1":3412,"PHASE1":3414,"PHASE2":3416,"PHASE3":3418,"PHASE4":3420,"NA":3422},{"trials":3413,"activeCount":99},[],{"trials":3415,"activeCount":99},[],{"trials":3417,"activeCount":99},[],{"trials":3419,"activeCount":99},[],{"trials":3421,"activeCount":99},[],{"trials":3423,"activeCount":99},[3424],{"nctId":3362,"briefTitle":3363,"status":105,"phases":3425,"primaryCompletion":3365,"completion":3365,"start":3366,"enrollment":3367,"conditions":3426,"interventions":3427},[],[29],[3347,3370,3371,3372,3373],{"intervention":3373,"totalTrials":140,"cells":3429},{"EARLY_PHASE1":3430,"PHASE1":3432,"PHASE2":3434,"PHASE3":3436,"PHASE4":3438,"NA":3440},{"trials":3431,"activeCount":99},[],{"trials":3433,"activeCount":99},[],{"trials":3435,"activeCount":99},[],{"trials":3437,"activeCount":99},[],{"trials":3439,"activeCount":99},[],{"trials":3441,"activeCount":99},[3442],{"nctId":3362,"briefTitle":3363,"status":105,"phases":3443,"primaryCompletion":3365,"completion":3365,"start":3366,"enrollment":3367,"conditions":3444,"interventions":3445},[],[29],[3347,3370,3371,3372,3373],{"intervention":3447,"totalTrials":140,"cells":3448},"SPIKEVAX",{"EARLY_PHASE1":3449,"PHASE1":3451,"PHASE2":3453,"PHASE3":3455,"PHASE4":3457,"NA":3459},{"trials":3450,"activeCount":99},[],{"trials":3452,"activeCount":99},[],{"trials":3454,"activeCount":99},[],{"trials":3456,"activeCount":99},[],{"trials":3458,"activeCount":99},[],{"trials":3460,"activeCount":99},[3461],{"nctId":3462,"briefTitle":3463,"status":105,"phases":3464,"primaryCompletion":3465,"completion":302,"start":1457,"enrollment":3466,"conditions":3467,"interventions":3468},"NCT06130345","Post-marketing Safety of Elasomeran\u002FDavesomeran and Andusomeran",[],"2024-02-29",15196685,[15],[3447]]